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Gene therapy is a promising approach for the treatment of neurological 
disorders in the central nervous system (CNS). Because of the complex 
structure and high vulnerability of the CNS, it is critical that the expression of a 
therapeutic gene is restricted within the target regions or cells, and the level 
and duration of the expression can be regulated as desired. With currently 
available promoters and gene delivery vectors, it remains a great challenge to 
temporally and spatially control the transgene expression in the CNS. The 
purpose of this study was to develop novel promoters that can drive high level 
and neuron- or glia-specific transgene expression in the CNS, and to test or 
modify viral vectors suitable to harbor these promoters. The ultimate objective 
of the study is to use these promoters and vectors for gene therapy of 
neurological disorders, particularly Parkinson’s disease (PD) and gliomas.  
 
In the first part of this study, a hybrid promoter constructed by fusing the 
enhancer of human cytomegalovirus immediate-early gene (CMV E) to the 
promoter of human platelet-derived growth factor B-chain (PDGF), namely 
CMV E/PDGF promoter, was tested in the context of Adeno-associated 
viruses type 2 (AAV-2) and baculovirus vectors to drive in vitro and in vivo 
transgene expression. A high level, neuron-specific and long-term transgene 
expression was achieved in rat striatum and substantia nigra with the AAV-2 
vectors, while a high level and neuron-specific, but only transient expression 
was observed with the baculovirus vectors. In addition, the baculovirus-
mediated neuron-specific expression was improved with the introduction of 
 X 
inverted terminal repeats (ITRs) of AAV by flanking the expression cassette in 
baculovirus vectors.  
 
Secondly, a hybrid astrocyte-specific promoter with high transcriptional 
activity, namely CMV E/GFAP promoter, was constructed by adding the CMV 
enhancer to the upstream of human glial fibrillary acidic protein (GFAP) 
promoter. In vitro and in vivo gene transfer showed that a high level and 
astrocyte-specific, but transient gene expression could be achieved with 
baculovirus vectors carrying the CMV E/GFAP promoter. ITRs could improve 
the baculovirus-mediated astrocyte-specific transgene expression as well.  
 
Thirdly, a hybrid baculovirus-AAV viral vector was constructed by 
incorporating the two key elements of AAV, the ITRs and the Rep gene, into 
the backbone of baculovirus. Promoters constructed in first two parts of this 
study were incorporated into this hybrid viral vector. Gene transfer 
experiments confirmed its capacity of mediating a stable transgene 
expression in human-originated cells by site-specific integration of the 
transgene into the host chromosome 19.  
 
In conclusion, the novel hybrid promoters constructed in this study displayed 
high and cell type-specific transcriptional activities, and suitable for neuron- or 
astrocyte-specific gene delivery to the CNS. By using AAV-2 vectors, 
baculovirus vectors with ITRs or hybrid baculovirus-AAV vectors, these 
promoters could be potentially applied for gene therapy for neurodegenerative 
diseases and possibly for malignant glioma tumors in the CNS. 
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Gene therapy, which can be defined as a correction or prevention of a 
disease by the use of genetic materials, has been regarded as a potential tool 
for many presently untreatable or poorly managed diseases, including both 
inherited and acquired diseases (Factor, 2001). Many neurological disorders 
in the central nervous system (CNS), such as the neurodegenerative diseases 
and malignant glioma tumors, are potentially amenable to gene therapy. Gene 
delivery to the CNS has been extensively studied in the last decade, with a 
variety of vectors, promoters and therapeutic genes, but limited progress has 
been achieved as compared to gene delivery to other organs, reflected by the 
small number of clinical trials on gene therapy of CNS diseases (Lowenstein 
and Castro, 2002). Greater challenges remain for gene delivery to the CNS 
than other organs because of the unique characters of the CNS, such as 
limited access, complex structure and high risk, etc (Hsich et al., 2002).  
 
The core issue and also a huge challenge for gene therapy of CNS disorders 
is to build up a safe and efficient delivery system to temporally and spatially 
control the expression of the therapeutic gene as desired. The promoter and 
vector are the two essential elements in a gene delivery system, controlling 
the level, specificity and duration of transgene expression at the 
transcriptional and the transductional level respectively. For gene therapy of 
neurological diseases in the CNS, it is important that a particular promoter 
and vector should be carefully selected, combined, and sometimes properly 
modified for the treatment of a particular condition. In this introduction, the 
current progress in gene therapy of some neurological disorders in the CNS 
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will be discussed, followed by overview of the progress made by using 
different types of promoters and vectors for gene delivery to the CNS.  
 
1.1 Current progress in gene therapy 
Gene therapy, which usually refers to somatic gene therapy, can be broadly 
defined as the treatment of a disease through the addition and expression of 
genetic materials that reconstitute or correct missing or aberrant genetic 
functions or interfere with disease-causing processes. The targets of gene 
therapy have been broaden from monogenetic diseases to multigenetic 
diseases, and further to acquired diseases (Factor, 2001). Three essential 
components are involved in gene therapy: a therapeutic gene, a regulatory 
element, usually a promoter, and a delivery vehicle, also named a vector 
(Russell, 1997).  
 
The therapeutic gene is selected according to the target disease. Originally, it 
was proposed to use the therapeutic gene for replacing the mutant gene. 
However, the replacement approach is complicated and remains difficult. 
More commonly and practically, the therapeutic gene is used to ameliorate 
diseases, either inherited or acquired, by enhancing, reducing or altering a 
particular gene expression in the target cells (Mountain, 2000). The promoter 
is one of the key issues of gene therapy. The expression level and specificity 
of the therapeutic gene is primarily determined by the activity of the promoter 
at the transcriptional level, and the duration of the transgene expression can 
also be influenced by the selection of promoters. The gene delivery vector 
that carries and transfers the gene into the nuclei of target cell is another key 
Chapter 1. Introduction 
 4 
issue of gene therapy. The tropism of the vector can essentially determine the 
cell type-specificity of the transgene expression at the transductional level, 
and the transduction efficiency of the vector will strongly affect the expression 
level. More importantly, the status of the transferred gene, integrated or 
episomal, will decide the duration of the transgene expression, which might be 
transient or long-term.  
 
More than a decade has been elapsed since the first clinical trial of gene 
therapy, and it is becoming increasingly clear that it is almost impossible to 
create an universal gene delivery system for the treatment of all diseases, or 
even for several similar diseases, since each disease has its specific 
requirements for the expression pattern of the therapeutic gene, and special 
technical obstacles to be overcome (Rubanyi, 2001). The various elements of 
a gene delivery system, especially the promoter and the vector, need to be 
optimized and combined specially for each particular application.  
 
1.2  Gene delivery to the CNS 
Gene delivery to the CNS, especially the brain, is drawing more and more 
attention recently. Many diseases occurring in the CNS, especially 
neurodegenerative disorders like Parkinson’s disease (PD) and malignant 
glioma tumors, are potentially amenable to gene therapy. Conventional 
treatments to these diseases such as surgery and invasive drug delivery, 
might cause big damage to the brain as repetitive operation is usually 
required, e.g. to remove recurrent brain tumors, or to inject drugs with short 
half-life. Gene therapy, on the other hand, can minimize this kind of damage 
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to the brain by a single delivery of genetic materials that might mediate a 
sustained and high-level expression of therapeutic gene.  
 
PD is a common neurodegenerative condition characterized by the 
degeneration of nigrostriatal dopaminergic neurons, with symptoms of rigidity, 
tremor, bradykinesia, and postural imbalance (Shastry, 2000). Unlike other 
neurodegenerative disorders such as Alzheimer’s disease (AD) that globally 
affect the nervous system and involves many types of cells, PD is confined 
primarily to a well-defined, compact group of neurons. Moreover, a variety of 
well-defined animal models have long been available by using neurotoxins 
such as 6-hydroxydopamine (6-OHDA), bringing PD to the forefront in studies 
of gene therapy for neurodegenerative diseases. Gene delivery of 
neurotrophic factors, mainly glial cell-line derived neurotrophic factor (GDNF), 
by viral vectors such as adenovirus, lentivirus and adeno-associated virus 
(AAV) vectors, to diseased dopamine neurons or astrocytes surrounding the 
neurons in the target area could prevent degeneration of dopamine neurons 
and rescue motor deficits (Raymon et al., 1997; Kordower et al., 2000; Sun et 
al., 2005). Direct gene delivery of the tyrosine hydroxylase (TH) that is 
responsible for the biosynthesis of L-Dopa from tyrosine in the striatum has 
also shown significant transgene expression (During et al., 1994). The major 
challenge for gene therapy of PD is to develop a safe vector that can provide 
high level of long-term transgene expression specifically in the target cells, 
neurons or astrocytes, in the affected area of the CNS. 
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Malignant glial tumors, also named glioblastoma multiforme (GBM) that 
originate from astrocytes, are the most common primary brain tumors in 
adults. Currently, GBM is almost incurable. Even with surgery, radiation, and 
chemotherapy, patients with GBM usually die within about a year, with few 
patients survive longer than 3 years. Specific delivery of therapeutic genes by 
viral vectors to malignant gliomas has proven to be a promising novel 
treatment (Sandmair et al., 2000; Smith and Chiocca, 2000). The difficulty for 
gene therapy of glioma tumors is how to restrict the delivered therapeutic 
gene within the tumor cells, since the expression of the therapeutic genes in 
normal cells will cause severe side effects and even cell death. 
 
Gene delivery to the brain, an organ so complex and critical to human 
integrity, raises some special issues like safety and risk-benefit ratio (Hsich et 
al., 2002). Furthermore, the limited access to the CNS due to the skull and the 
blood brain barrier (BBB), the complex structure with numerous functional 
domains and circuitries, and the great diversity of the cell types in the CNS 
greatly increase the difficulty of gene delivery. In sight of these considerations, 
special attention has to be paid to the gene delivery system, especially to the 
safety issue which is related to the vector and the temporal and spatial control 
of the transgene expression. In the following sections, some currently used 
promoters and viral vectors for gene delivery to the CNS will be discussed.  
 
1.3  Promoters used for gene delivery to the CNS  
Numerous promoters have been employed to control the transgene 
expression in the CNS, including viral-based promoters, mammalian 
Chapter 1. Introduction 
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promoters and some composite promoters, also named hybrid promoters. 
Some other DNA regulatory elements, such as the posttranscriptional 
regulatory element of woodchuck hepatitis virus (WPRE) and inverted 
terminal repeats (ITRs) of AAV, were also used alongside with the promoters 
to regulate the transgene expression. By using an appropriate promoter and 
proper DNA regulatory elements, the expression level, specificity and duration 
can be regulated as desired at the transcriptional level. 
 
1.3.1 Promoters derived from viral genomes 
Viral promoters have been widely employed for gene delivery to the CNS 
during the early times of gene therapy. The mostly used viral-based promoter, 
the promoter of cytomegalovirus (CMV) immediate-early genes, has been 
demonstrated to drive strong transgene expression in the brain, and was used 
for gene delivery to the CNS (Schmidt et al., 1990; Wilkinson and Akrigg, 
1992; Kaplitt et al., 1994; McCown et al., 1996). Other viral-based promoters 
used for CNS gene delivery include the simian virus 40 (SV40) promoter and 
viral long terminal repeat (LTR) promoter from Rous sarcoma virus (RSV), 
retrovirus and Moloney murine leukemia virus (Takekoshi et al., 1991; Mandel 
et al., 1999; Shimazaki et al., 2000). 
  
Although a high level of transgene expression can be achieved with these 
viral-based promoters, such viral transcriptional elements are usually non-
specific, being active in a wide variety of cell types. Using viral-based 
promoters for gene delivery to the CNS will lead to side effects like expression 
of the therapeutic gene in nontarget cells, which may prove pathological, 
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causing severe damage to the brain. Another disadvantage associated with 
viral-based promoters is the inactivation of the promoters in mammalian cells, 
which might be mainly due to the methylation of viral DNA in mammalian cells 
(Prosch et al., 1996). Such inactivation is indicated with the gradual decline of 
the transgene expression driven by viral promoters. Depending on the vector 
system, gene expression driven by CMV promoter can be maintained at a 
relatively high level for various durations, from days to months, and drop 
rapidly after that due to the inactivation (Prosch et al., 1996; Brooks et al., 
2004; Everett et al., 2004). The short-term expression driven by viral-based 
promoter limits their application for gene therapy of neurological disorders in 
the CNS, especially neurodegenerative diseases like PD, which require a 
long-term expression of the therapeutic gene.   
 
1.3.2  Mammalian promoters 
As compared to viral promoters, mammalian promoters can restrict the 
transgene expression within the target cells, therefore minimizing the side 
effects caused by unintended transduction. Moreover, mammalian promoters 
may be less likely to activate host cell defense machinery because of their 
authentic sequences, thus are usually less sensitive to cytokine-induced 
promoter inactivation than viral promoters (Dressel et al., 2000). Therefore, a 
cell type-specific and more stable transgene expression usually can be 
achieved with a mammalian promoter than with a viral promoter. Two kinds of 
mammalian promoters, which can drive specific transgene expression in 
neurons and glial cells respectively, were commonly used for gene delivery to 
the CNS. 
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Neuron-specific promoters, such as the promoter of neuron-specific enolase 
(NSE) and the promoter of human platelet-derived growth factor B chain 
(PDGF), have been used to drive neuron-specific transgene expression in the 
brain. NSE promoter was first shown to drive a high level of neuronally 
restricted lacZ expression in a transgenic mouse study (Forss-Petter et al., 
1990). It was also found to facilitate a very high level of AAV-mediated 
transgene expression in the CNS (Peel et al., 1997). Another widely used 
neuron-specific promoter is the human PDGF promoter, which was shown to 
specifically target transgene expression to neurons in transgenic mouse 
studies (Masliah et al., 2000). AAV vector with the PDGF promoter has been 
shown to drive transgene expression at the rat substantia nigra for at least 1 
month postinjection (Furler et al., 2001). 
 
The promoter of myelin basic protein (MBP) and the promoter of glial fibrillary 
acidic protein (GFAP) are two promoters that have been employed to drive 
glia-specific transgene expression in the CNS. BMP promoter was 
demonstrated to direct expression specifically to oligodendrocytes (Gow et al., 
1992), while GFAP promoter was described as an astrocyte-specific promoter 
(Brenner et al., 1994). GFAP promoter was also widely used for specific gene 
delivery to malignant gliomas that originated from astrocytes (Vandier et al., 
2000). 
 
Although these neuron- or glia-specific promoters can drive cell type-specific 
and sometime sustained transgene expression in the CNS, their 
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transcriptional activities are relatively low as compared to a viral promoter like 
CMV promoter. Under the control of those mammalian promoters, transgene 
expression is usually maintained at the physiological level, which might be not 
high enough to achieve significant therapeutic effects for the chronic 
neurological diseases and glioma tumors.  
 
1.3.2 Hybrid promoters  
The relatively low transcriptional activity of mammalian promoter has led to 
significant research efforts to improve their strength for applications where 
high level and cell type-specific gene expression are required (Iyer et al., 
2001; Wang et al., 2003; Ionescu et al., 2004). One approach successfully 
applied to several mammalian promoters is appending a viral transcriptional 
regulatory element to a mammalian promoter to create a composite, also 
called hybrid promoter (Nettelbeck et al., 1998). SV40 enhancer and CMV 
enhancer, both are strong viral regulatory elements of quite small sizes, which 
are most commonly used to fuse with mammalian promoters with weak 
transcriptional activities (Niwa et al., 1991; Sawicki et al., 1998). Compared to 
the original mammalian promoter, the hybrid promoter can usually drive 
transgene expression at high levels and sometime with retained cell type 
specificity. 
 
The CMV enhancer/beta-actin (CAG) promoter is a widely used hybrid 
promoter that is composed of the CMV enhancer fused to the chicken 3/4 
actin promoter. CAG promoter has been shown to have a higher activity in 
most tissues, as compared to the CMV promoter or beta-actin promoter (Yew 
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et al., 2001). An AAV vector carrying a CAG promoter could drive a 137-fold 
higher expression of human factor X than the CMV promoter in the liver of 
mice (Xu et al., 2001a). Hybrid promoters for improved liver specific transgene 
expression were also developed. Hepatocyte-specific enhancers like the 
alpha1-microglobulin/bikunin (ABP) enhancer and apolipoprotein E (apoE) 
enhancer were linked with core promoters like alcohol dehydrogenase 6 
(ADH6) promoter and human alpha-antitrypsin (hAAT) promoter to construct a 
variety of hybrid promoters, among which the apoE enhancer/ADH6 promoter 
could drive a highly efficient and specific transgene expression in liver cells 
(Gehrke et al., 2003).  
 
A hybrid neuron-specific promoter, namely CMV E/PDGF promoter, was 
previously constructed by combining the CMV enhancer with the human 
PDGF promoter (Liu et al., 2004). When used with a polyethyleneimine (PEI) 
/DNA delivery system, this promoter can drive in vivo expression of a 
luciferase reporter gene at high level while preserving neuronal specificity. 
However, the transgene expression driven by this hybrid CMV E/PDGF 
promoter in viral vectors has not been assessed yet. Using this strategy might 
also hopefully improve the relatively low transcriptional activity of the GFAP 
promoter, thus propelling its application for high level astrocyte-specific gene 
delivery to the CNS.  
 
1.3.4  Other DNA elements regulating the gene expression 
Besides the promoters, some other DNA elements are also used to regulate 
the transgene expression in mammalian cells. WPRE is one of the DNA 
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elements that have been used to improve the transgene expression. It has 
been reported that insertion of the WPRE into the 3' untranslated region of 
coding sequences carried by either retroviral or lentiviral vectors substantially 
increased their levels of expression in a transgene-, promoter- and vector-
independent manner (Zufferey et al., 1999). This effect of WPRE on level of 
gene expression could also be observed in other viral vectors including AAV 
(Paterna et al., 2000) and adenovirus (Mian et al., 2004; Glover et al., 2005). 
 
The ITRs of AAV is another DNA element that is often used to improve the 
transgene expression. Several groups have developed viral or plasmid 
vectors with the expression cassette flanked by ITRs, and reported improved 
efficiency of transgene expression in mammalian cells (Philip et al., 1994; 
Vieweg et al., 1995; Johnston et al., 1997; Costantini et al., 1999; Lam et al., 
2002; Xin et al., 2003; Chikhlikar et al., 2004), xenopus embryos (Fu et al., 
1998), and fishes (Chou et al., 2001; Hsiao et al., 2001). 
 
1.4  Vectors used for gene delivery to the CNS  
Three types of gene delivery methods, namely physical methods, non-viral 
methods and viral methods, have been applied for gene delivery to 
mammalian cells. Physical delivery methods, such as needle-free injection,  
often named “gene gun” or “Jetgun”, which push DNA coated particles into 
cells or tissues, and electroporation, which deliver DNA to cells by using an 
electric field to transiently break down the cell membrane, have been 
developed (Mathei et al., 1997; Tacket et al., 1999). However, they have not 
been extensively used for gene therapy applications, and were rarely used for 
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gene delivery to the CNS because of their poor in vivo performance. Non-viral 
and viral vectors are therefore commonly used for gene delivery into the CNS 
because of their higher transduction efficiency.  
 
1.4.1  Non-viral vectors  
Non-viral vectors can be divided into three main categories: naked DNA, 
cationic lipids and cationic polymers. Naked DNA can provide a very efficient 
gene transfer in muscle and skin by in vivo local injection, although the 
mechanism of its entry into the cells remains unknown. Its application for gene 
delivery into the CNS is hampered by the low efficiency in neural cells and 
short-term transgene expression (Hengge et al., 1995). Cationic lipids are 
very popular non-viral vectors for gene delivery. They can bind DNA by 
electrostatic interaction and provide substantial protection from degradation, 
with efficient in vitro transduction and reasonable in vivo transduction in the 
lungs (Alton et al., 1993; Ewert et al., 2004). However, using cationic lipid for 
gene delivery for other organs of the body is not common because of the 
instability of the preparations, heterogeneity and poor targeting. Cationic 
polymers like polylysine, PEI and oligopeptides can condense DNA into small 
particles by electrostatic interaction, thus protecting it from degradation and 
enhancing uptake via endocytosis. Although in vitro transduction with cationic 
polymers was efficient, in vivo result was not promising, probably due to the 
fact that particles forming from DNA condensed with cationic polymer are 
usually too large to be efficiently taken up by most cell types and also too 
large to penetrate through some solid tissues. Furthermore, following the 
uptake by the cell, cationic polymers become trapped in the endosome and 
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require addition of an exogenous endosome-disruption agent, which is not 
applicable in vivo (Davis, 2002; Cho et al., 2003).  
 
Therefore in spite of their advantages such as no limitation on the size of 
constructs and ease of manufacturing, non-viral vectors are less commonly 
used for gene delivery to the CNS than viral vectors (Abdallah et al., 1995; 
Wolff and Trubetskoy, 1998; Ruponen et al., 2003).  
 
1.4.2  Viral vectors 
Viral vectors are the most efficient vectors to transduce mammalian cells, and 
therefore are employed in most gene delivery experiments. A variety of viral 
vectors, including adenovirus, retrovirus, Herpes simplex virus (HSV), AAV, 
and, more recently, baculovirus have been applied for gene delivery to the 
CNS (Lundstrom, 2003).  
 
Retroviruses are lipid-enveloped particles comprising a homodimer of linear, 
positive-sense, single-stranded RNA genomes of 7 to 11 kb, with two LTR 
sequences at their ends. After entering into the target cells, the RNA genome 
is retro-transcribed into linear double-stranded DNA and integrated into the 
cell chromatin randomly. Although retrovirus can mediate long-term gene 
expression by chromosomal integration, it might also activate some pro-
oncogenes by the random insertion (VandenDriessche et al., 2003). Moreover, 
the inability to infect non-dividing cells and the possibility of causing 
immunodeficiency has also restricted its application for gene delivery to the 
CNS (Coffin et al., 2000). 
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Adenoviruses are icosahedral particles composing of a viral capsid that 
surrounds the viral core containing large DNA genome of 36 kb. The use of 
recombinant adenovirus as a gene delivery vector is facilitated by its ability to 
generate high-titer stocks and the high level of heterologous gene expression 
(Brody and Crystal, 1994; Hitt et al., 1997). However, although new 
generations of adenoviruses have been created with decreased toxicity 
profiles in animals, the fatality report from an E1/E4 deleted adenovirus 
infused into the hepatic artery of a young man with partial ornithine 
transcarbamylase (OTC) deficiency severely hampered the application of 
adenoviruses for human gene therapy (Lusky et al., 1998; Schiedner et al., 
1998; Raper et al., 2003). 
 
HSV vector, with typical characteristics of large genome (152 kb), 
neurotropism and episomal state in the cell neucleus, was one of the viral 
vectors suitable for gene delivery to the CNS (Krisky et al., 1998). However, 
the cytotoxicity and short-term gene expression mediated by HSV hampered 
its application for gene therapy of disorders in the CNS. 
 
AAV is a human parvovirus that normally requires a helper virus, such as 
adenovirus, to mediate a productive infection (Muzyczka, 1992). No known 
disease was found to associate with AAV infection, making it a very safe 
candidate for gene therapy. The viral genome consists of two genes, namely 
Rep and Cap, which are flanked by viral inverted terminal repeat sequences 
(ITRs) that are 145 nucleotides in length. In recombinant AAV vector 
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generated for gene delivery, the Rep and Cap genes are replaced by the 
therapeutic genes. AAV is a commonly used viral vector, especially for gene 
delivery to the CNS, mainly because of its low cytotoxicity, ability to drive 
long-term transgene expression and high tropism for neurons. AAV can 
integrate the transgene into a host genome at chromosome 19q13.4qtr 
(AAVS1) via the function of ITRs and Rep gene, therefore mediating a long-
term transgene expression, with longest report of several years. The site-
specific integration mediated by AAV vectors can help to avoid the activation 
of pro-oncogenes by the random integration (Rabinowtz and Samulski, 1998). 
The disadvantages of AAV as a gene delivery vector are its small packaging 
capacity and the inconvenience of large-scale preparation of viral stock 
(Rabinowtz and Samulski, 1998).  
 
Baculoviruses constitute a group of double stranded DNA viruses that cause 
lethal diseases of arthropods. The best studied member of this family, 
Autographa californica nuclear polyhedrosis virus (AcMNPV), is a large 
enveloped virus with a double-stranded, circular DNA genome of ~130 kb. 
Baculovirus is a recently developed gene delivery vector. It has long been 
used as biopesticide and a tool for recombinant protein expression in insect 
cells (O’Reilly et al., 1994). Recently, it was found that baculovirus could 
efficiently transfer and express target genes in mammalian cells, with high 
transduction efficiency comparable to that of adenovirus (Aireene et al., 2000; 
Kost and Condreay, 2002). The advantages of using baculovirus as gene 
delivery include large cloning capacity, ease of preparation of virus stock with 
high titer and the lack of obvious pathogenicity to mammals. Baculovirus is 
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considered as the safest viral vector for humans because it is an insect virus 
that cannot express any viral gene in mammalian cells. The main limitation of 
baculovirus-mediated transgene expression is the short expression period, 
which is especially undesirable for gene therapy of neurodegenerative 
diseases in the CNS (Kost and Condreay, 2002). 
 
Although a variety of viral vectors have been developed during the past few 
years and continuous improvements were made to make those vectors safer 
and more efficient for gene therapy, it has become obvious that each viral 
vector has its inherited disadvantages for gene delivery to the CNS. 
Therefore, it might be very attractive to combine two viruses together to create 
a hybrid viral vector which may inherit advantages from both vectors. 
 
1.4.3  Hybrid viral vectors 
As mentioned above, the biggest limitation of most commonly used viral 
vectors for gene delivery to the CNS is that they cannot maintain the 
transgene expression for a long time. On the other hand, AAV vectors can 
maintain long-term transgene expression by site-specific integration, but they 
have other limitations such as small capacity for foreign genes. Therefore, it 
would be very desirable to incorporate the elements responsible for 
integration of AAV to other viral vectors to improve their performance by 
prolonging the duration of expression. ITRs and Rep genes are the two 
elements that are responsible for the site-specific integration of AAV, and 
have been used to create hybrid viral vectors, solely or together. 
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It has been reported that a helper-dependent, gutless adenovirus vector 
carrying a transgene flanked by ITRs of AAV can stably transduce hepatoma 
cells with the transgene integrated into the AAVS1 locus of host choromosome 
19 (Recchia et al., 1999). However, the generation of this helper-dependent 
adenovirus-AAV hybrid vector was accompanied by a very large 
contamination by helper adenovirus particles. The cytotoxicity and 
immunogenecity of the helper adenovirus pose limitations on applying the 
hybrid adenovirus-AAV vector for gene therapy of CNS diseases. 
 
Hybrid HSV-AAV vectors which could direct long-term transgene expression 
in both gliomas and neuronal cells have also been constructed by combining 
the high infectibility and large transgene capacity of HSV with the potential for 
episomal amplification and chromosomal integration of AAV (Johnston et al., 
1997; Costantini et al., 1999). However, the cytotoxicity associated with HSV 
makes the hybrid HSV-AAV vectors unsafe for gene delivery to the CNS. 
 
Baculovirus attracted the attention of researchers recently as a means to 
create a safe hybrid viral vector for gene delivery to the CNS,. By combining 
the elements from AAV with baculovirus, a hybrid baculovirus-AAV viral vector 
can be created, which is safe for human, and can direct long-term transgene 
expression. Palombo et al. (1998) first created this hybrid viral vector by 
combining the key elements of AAV with the high transducing capacity of 
baculovirus. Infection of HEK 293 cells with this hybrid vector resulted in very 
efficient transduction and specific integration of the transgene into the AAVS1 
locus of chromosome 19. Since baculovirus is a newly developed vector, its 
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characteristics have not been clearly studied in sufficient details, and its 
application for gene delivery is very limited. The findings of Palombo et al. 
(1998) have attracted little attention hitherto. Although this pioneering study 
only examined the ability of site-specific integration of the hybrid viral vector, it 
did reveal the possibility of a safe and long-term transgene expression in the 
CNS using the hybrid baculovirus-AAV vector.  
 
1.5 Objectives of this study 
Promoters and vectors are the two key elements of gene delivery system, 
regulating the transgene expression in the target mammalian cells temporally 
and spatially at both transcriptional and transductional levels. To build up 
suitable delivery systems for gene therapy of neurological diseases in the 
CNS, appropriate promoters and vectors should be selected, combined 
together and sometime properly modified. The objective of this study was to 
set up safe and efficient gene delivery systems for neurological disorders in 
the CNS, particularly the neurodegenerative disorders like PD and malignant 
glioma tumors. This could be achieved by using novel engineered mammalian 
promoters and other DNA regulatory elements like ITRs from AAV in 
appropriate viral vectors like AAV, baculovirus, and/or hybrid baculovirus-AAV 
vector. The specific objectives were: 
 
1. To examine the in vitro and in vivo transgene expression mediated by the 
previously constructed hybrid CMV E/PDGF promoter in AAV-2 vector, 
baculovirus vector, or baculovirus vector carrying ITRs from AAV. 
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Application of this hybrid promoter for high level and neuron-specific gene 
delivery to the CNS was also to be investigated. 
 
2. To create an astrocyte-specific promoter with high transcriptional activity 
by appending a CMV enhancer before the GFAP promoter. In vitro and in 
vivo transgene expression driven by this CMV E/GFAP promoter will be 
examined in baculovirus vector or baculovirus vector carrying ITRs of 
AAV.  Application of this promoter for high level and astrocyte-specific 
gene delivery to the CNS was also to be investigated. 
 
3. To generate a hybrid baculovirus-AAV viral vector by incorporating both 
the ITRs and the Rep gene of AAV into the context of baculovirus.  The 
hybrid promoters mentioned above were also tested in this hybrid viral 
vector to explore the feasibility of achieveing a high level, long-term and 
cell type-specific transgene expression in the CNS. 
 
The vectors developed in the course of this study might provide useful for 
gene delivery treatments of some neurodegenerative diseases and glioma 
tumors in the CNS. In the present study only luciferase reporter gene was 
used. In future, therapeutic genes could be carried by the gene delivery 
systems developed in this study and be specifically delivered to the target 
cells for the treatment of some neurological diseases in the CNS.  
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2.1  Introduction 
Gene therapy has been considered as a potential approach to the treatment 
of neurological disorders. To achieve this goal, several obstacles to successful 
gene transfer that are related to unique attributes of the central nervous 
system (CNS) must be overcome. One of the obstacles is the great diversity 
of cell types in the CNS, many of which have critical physiological functions 
and are highly sensitive to change. This underscores the importance of 
restricting expression of a therapeutic gene to a particular type of cells, thus 
ensuring limiting side effects caused by gene expression in nontarget cells.  
 
Neurons are the major functional cells in the nervous system, carrying out the 
fundamental tasks of receiving, conducting and transmitting signals. 
Therapeutic protection of these cells is one of the main goals of gene therapy 
of neurological disorders. Examples include protection of dopaminergic 
nigrostriatal neurons in Parkinson’s disease (PD), cholinergic neurons in 
Alzheimer’s disease (AD), and spinal motoneurons in amyotrophic lateral 
sclerosis. Using a mammalian promoter is a particularly attractive approach of 
restricting gene expression to the neurons in the CNS (Miller and Vile, 1995). 
In addition to offering neuron-specific gene expression, mammalian 
promoters, because of their authentic sequences, may be less likely to 
activate host cell defense machinery, thus are usually less sensitive to 
cytokine-induced promoter inactivation than viral promoters (Dressel et al., 
2000). Therefore, the improved stability of gene expression can be expected.  
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Several mammalian promoters that are specific to neurons have been used 
for neuron-specific gene delivery to the CNS (Fitzsimons et al., 2002), among 
which is the promoter of human platelet-derived growth factor B-chain 
(PDGF), which can direct the expression of transgenes to differentiated 
neurons in the cortex, cerebellum, brainstem, spinal cord and olfactory bulb in 
transgenic animals (Sasahara et al., 1991). However, such mammalian 
promoters usually exhibit weaker transcriptional activities than viral promoters. 
For example, in cultured cells, the PDGF promoter in the pGL3-basic vector 
exhibited much lower transcriptional activity than viral promoters, including the 
promoter of cytomegalovirus (CMV) immediate-early gene, the Rous sarcoma 
virus (RSV) promoter and the simian virus 40 (SV40) promoter, and also 
lower than other mammalian promoters, including elongation factor 1 a 
(EF1a) promoter and Ta 1 tubulin promoter. These observations have led to 
significant research efforts to improve the strength of mammalian promoters 
(Veelken et al., 1998; Iyer et al., 2001; Wang et al., 2003; Ionescu et al., 
2004). 
 
One approach that has been successfully applied to several mammalian 
promoters is to append a viral transcriptional regulatory element to a 
mammalian promoter (Nettelbeck et al., 1998). In several previous studies 
CMV enhancer (CMV E) region 5¢ was fused to a mammalian promoter to 
increase its transcriptional activity (Robinson et al., 1995; Sawicki et al., 1998; 
Yew et al., 2001). A hybrid CMV E/β-actin (CAG) promoter carried by an 
adeno-associated virus type 2 (AAV-2) vector could drive a 137-fold higher 
expression of human factor X than CMV promoter did in the liver of mice (Xu 
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et al., 2001a). Liu et al. (2004) had previously tested the feasibility of using 
this method to improve the strength of the PDGF promoter. The hybrid CMV 
E/PDGF promoter was placed into a plasmid DNA (pDNA) vector and 
delivered into cells by polyethylenimine (PEI)/pDNA complex. It was found to 
function preferentially in neurons over glial cells. Improved gene expression 
levels in cultured neurons and prolonged gene expression in the brain when 
compared with CMV promoter were also observed. The expression level in 
the brain, however, was still lower than that provided by CMV promoter within 
the first week post-injection and decreased gradually after 2 weeks. 
Furthermore, it was unclear whether neuronal specificity was preserved in the 
CMV E/PDGF promoter, because powerful viral transcriptional control 
elements could alter the desired specificity offered by a mammalian promoter 
after it has been placed in viral vectors (Miller and Whelan, 1997).  
 
AAV vectors, especially type 2, are highly promising tools for gene therapy of 
neurological disorders due to their natural tropism for neurons, low 
immunogenicity/toxicity and ability to persistent transgene expression. 
Although AAV are known to be able to integrate into the host chromosomes, a 
study in hepatocytes has identified episomal, not integrated, genomes as the 
major form of AAV-2 vectors and the primary source of persistent gene 
expression from AAV-2 (Nakai et al., 2001). Vector genome 
concatemerization and/or the presence of the inverted terminal repeats (ITRs) 
might be the possible mechanistic reasons for the episomal persistence in 
nuclei (Philip et al., 1994; Duan et al., 1998; Nakai et al., 2001). However, the 
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cloning capacity of AAV genome limits the use of such vectors for delivery of 
large therapeutic genes.  
 
The baculovirus vector is emerging as a promising gene delivery agent 
capable of efficiently transferring genes of interest to a broad range of 
mammalian cell types. Empirical advantages of baculoviruses as gene 
therapy vectors also include large cloning capacity, ease preparation of virus 
stock with high titer and the lack of obvious pathogenicity. Being non-
mammalian viruses, baculoviruses are unable to replicate and express viral 
proteins in mammalian cells, thus significantly reducing the chance of vector 
neutralization caused by pre-existing antiviral immunity in patients and 
offering a possibility of re-administration of the viral vector as needed (Ghosh 
et al., 2002; Kost and Condreay, 2002). After systemic delivery, baculoviruses 
are inactivated easily by serum complement (Hofmann and Strauss, 1998). 
The CNS, protected by the blood-brain barrier (BBB), is virtually isolated from 
circulating immunological factors including complement components (Carson 
and Sutcliffe, 1999), making it to be a suitable organ for baculovirus-mediated 
gene expression. Direct injection of baculovirus vectors to the brain, using a 
thin needle and slow injection to avoid hemorrhage, could give satisfactory 
levels of transgene expression (Sarkis et al., 2000; Li et al., 2004; Li et al., 
2005).  After accommodating an appropriate neuron-specific promoter, 
baculovirus vectors provide clearly detectable levels of neuronal gene 
expression at the injection site, as well as in remote target regions due to 
axonal transport of the vectors taken up by the nerve terminals (Li et al., 
2004). The main limitation of baculovirus-mediated transgene expression is 
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the short expression period, which is especially undesirable for gene therapy 
of neurodegenerative diseases in the CNS (Kost and Condreay, 2002). 
 
ITRs of AAV has been reported to improve viral- or plasmid-mediated 
transgene expression in mammalian cells (Philip et al., 1994; Vieweg et al., 
1995; Johnston et al., 1997; Costantini et al., 1999; Lam et al., 2002; Xin et 
al., 2003; Chikhlikar et al., 2004), xenopus embryos (Fu et al., 1998), and 
fishes (Chou et al., 2001; Hsiao et al., 2001). It is, however, still not clear 
whether the effectiveness of this approach could be influenced by choice of 
promoters, gene delivery vectors and targeted tissues. Specifically, the 
feasibility of using this approach to improve the activity of a neuron-specific 
promoter in the context of baculovirus vectors in the nervous system has not 
yet been assessed. 
 
The present study assessed the transcriptional strength, expression duration 
and neuron specificity of the recently developed hybrid CMV E/PDGF 
promoter in the context of AAV-2 and baculovirus vectors, the two safest viral 
vectors available for humans. In addition, whether the ITRs of AAV could 
improve gene expression driven by baculovirus vectors harboring a neuron-
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2.2   Materials and methods 
2.2.1  Plasmids for AAV-2 vectors 
The hybrid CMV E/PDGF promoter, CMV promoter and PDGF promoter have 
been cloned into pGL3-basic plasmid previously (Liu et al., 2004). To produce 
AAV-2 vectors, these promoters were sub-cloned into a modified pAAV 
plasmid in which the expression cassette is flanked by the ITR sequences. 
This pAAV plasmid, named as pAAV-MCS-luc, was constructed by replacing 
the original sequence between the two Not I sites of plasmid pAAV-MCS 
(Stratagene, La Jolla, CA) by a MCS-luciferase-polyA expression cassette 
that was PCR amplified from pGL3-basic plasmid (Promega, USA) with 
forward primer, 5-ATTGCGGCCGCGGTACCGAGCTCTTACG and reverse 
primer, 5-ATTGCGGCCGCTTATCGATTTTACCACATTTG. The CMV 
E/PDGF promoter, CMV promoter and PDGF promoter were then cut from 
pGL3-basic plasmid and inserted into pAAV-MCS-luc between the Kpn I and 
Hind III sites respectively, to generate pAAV-CMV E/PDGF, pAAV-PDGF and 
pAAV-CMV. Fig. 2.1 shows the expression cassettes of recombinant AAV 
vectors used in this study. All plasmids were amplified in Escherichia coli 
DH5α strain and prepared using Qiagen plasmid Maxi-prep Kit (Qiagen, 
Ontario, Canada). 
 
2.2.2  Production and titration of AAV-2 vectors 
HEK293 (human embryonic kidney) cells were cultured with Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) in 100 
mm tissue culture dishes. The cells with 70-80% confluence were co-
transfected with one of the above recombinant pAAV plasmids, AAV-2 
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packaging plasmid pAAV-RC and adenovirus helper plasmid pHelper 
(Stratagene, La Jolla, CA), 10 mg of each plasmid per dish, at 1:1:1 molar ratio 
by calcium phosphate method. Seventy-two hours after the transfection, AAV-
2 vectors that had been packaged in the transfected HEK293 cells were 
released from collected cells by two rounds of freeze/thaw cycles and purified 
by a single-step gravity-flow heparin affinity column, as reported (Aurricchio et 
al., 2001). Briefly, the crude cell lysate containing AAV-2 vectors was 
incubated with DNase I and RNase A (Roche Biochemicals, Mannheim, 
Germany) at 37°C for 30 min, and then centrifuged at 3000 rpm for 15 min. 
The supernatant was incubated with 0.5% deoxycholic acid (Sigma, St. Louis, 
MO) at 37°C for 30 min, and then filtered and applied to a heparin column. 
The column was washed by PBS, pH7.4, plus 0.1 M NaCl. AAV-2 vectors 
were then eluted with PBS, pH7.4, plus 0.4 M NaCl. The elution containing 
the purified AAV-2 vectors was desalted and concentrated to desired volume 
with a filter column (Microcon YM-100, Millipore) by centrifugation at 3000 
rpm,  and then incubated at 56°C for 30 min to inactivate any contamination.  
 
The titers of AAV-2 vectors were determined by a sandwich enzyme linked 
immunosorbent assay (ELISA) based on a monoclonal antibody that 
selectively recognizes assembled AAV-2 capsids. The titration was carried out 
according to the supplier’s protocol (Progen, Germany). To evaluate the 
reliability of the titration by ELISA assay, the titers of AAV-2 vectors were 
further examined by quantitative real-time PCR in the DNA engine Opticon 2 
Thermal Cycler (MJ Research, USA) using the luciferase gene-specific 
primers 5’CGGGCGCGGTCGGTAAAG3’ and 
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5’ACTTCAGGCGGTCAACGAT3’, and SYBR Green (Roche Molecular 
Biochemical, Mannheim, Germany) for detection of PCR products. AAV-2 
vectors were digested first with DNase I to eliminate unpackaged DNA, 
followed by incubation with proteinase K (Boehringer, Germany). pAAV 
plasmids containing the expression cassettes were diluted to known 
concentrations (number of templates), and were used as internal standards 
for AAV-2 vectors respectively. The percentage of full particles versus total 
particle is 11.6% for AAV-CMV, 13.8% for AAV-PDGF and 12.3% for AAV-






Fig. 2.1 Schematics of the expression cassettes of the recombinant AAV 
vectors used in this study. Abbreviations: CMV, the promoter of CMV 
immediate-early gene; CMV E, the enhancer of CMV immediate-early gene (-
568 to -187 relative to the TATA box of the promoter of CMV immediate-early 
gene); PDGF, the PDGF promoter; Luc, luciferase gene; pA, polyA tail; ITR, 




2.2.3 Generation of recombinant baculovirus vectors 
pFastBac1 plasmid (pFB1; Gibco BRL, Life Technologies, Gaithersburg, MD, 
USA) was used as the transfer plasmid for the construction of recombinant 
baculovirus vectors. The hybrid CMV E/PDGF promoter or the CMV promoter 
was inserted into pFastBac1 between the sites of Not I and Xba I. Luciferase 
was used as the reporter gene for all the constructions and was inserted into 
the downstream of the promoters, between the sites of Xho I and Hind III. For 
CMV Luc pAAAV-CMV
PDGF Luc pA
PDGF Luc pACMV E
AAV-PDGF




Chapter 2. Hybrid Neuron-Specific Promoter 
 30 
the construction of baculovirus vector with ITRs of AAV, an expression 
cassette containing a MCS, a reporter gene encoding luciferase, a SV40 
polyA signal, and two ITR sequences at both ends was amplified from pAAV 
plasmid, and inserted into pFB1 between Avr II and Sal I. The CMV E/PDGF 
promoter was then inserted into the sites of Kpn I and Hind III to drive the 
luciferase reporter gene. Fig. 2.2 shows the expression cassettes of 
recombinant baculovirus vectors used in this study.  
 
Recombinant baculovirus vectors with the luciferase gene under the control of 
the CMV promoter, the hybrid CMV E/PDGF promoter and the hybrid CMV 
E/PDGF promoter plus ITRs of AAV were produced and propagated in sf9 
insect cells according to the manual of the Bac-to-Bac baculovirus expression 
system (Gibco BRL, Life Technologies, Gaithersburg, MD, USA), and named 
BV-CMV, BV-CMV E/PDGF and BV-CMV E/PDGF-ITR, respectively. Budded 
viruses in the sf9 insect cell culture medium were collected and filtered 
through a 0.45-mm pore size filter (Minipore, Bedford, MA, USA) to remove 
any possible contamination, and concentrated by ultracentrifugation at 28,000 
g for 60 min. Viral pellets were resuspended in appropriate volumes of 0.1 M 
phosphate-buffered saline (PBS) and their infectious titers (plaque-forming 













Fig. 2.2 Schematics of the expression cassettes of the recombinant 
baculovirus vectors used in this study. Abbreviations: CMV, the promoter of 
CMV immediate-early gene; CMV E, the enhancer of CMV immediate-early 
gene; PDGF, the PDGF promoter; Luc, luciferase gene; pA, polyA tail; ITR, 
inverted terminal repeats 
 
2.2.4  In vitro transduction with viral vectors and PEI/DNA complexes 
NT-2 cells were obtained from ATCC (American Type Culture Collection, 
Manassas, VA, USA), and maintained in DMEM with 10% FBS. Neuronal 
differentiation was induced by trans-retinoic acid (0.01 mM) and differentiated 
cells (NT2N) were seeded in 48-well plates with a density of 2 × 104 cells/well. 
C17.2 cells, a neural stem cell line, were grown in DMEM with 4 mM L-
glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 
1.0 mM sodium pyruvate and 10% fetal bovine serum (FBS). The cells were 
differentiated by plating them onto poly-L-lysine (50 mg/ml) and laminin (20 
mg/ml) coated 48-well plates at a density of 2 × 104 cells/well in serum-free 
DMEM/F12 media with 1% N2 supplement (Invitrogen, Netherlands) for 2 
days. Under these differentiation conditions, over 90% of the cells displayed 
neuronal morphology and were positively stained using antibodies against 68 
kDa neurofilament protein. PC12 rat pheochromocytoma cells were obtained 
from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 medium 
supplemented with 10% FBS and 5% horse serum. PC12 cells were 
differentiated at a density of 5× 104 cells/well in 24-well plates coated with 0.2 
CMV Luc pABV-CMV
PDGF Luc pACMV EBV-CMV E/PDGF
BV-CMV E/PDGF-ITR PDGF Luc pACMV EITR ITR  
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mg/ml rat-tail collagen in serum-free RPMI-1640 medium containing 50 ng/ml 
nerve growth factor (NGF) for 10 days. The percentage of cells possessing 
neurites was about 90%. 
 
Primary cortical neurons and glial cells were prepared form embryonic Wistar 
rats. The brains were collected and digested in a trypsin solution (0.25% 
trypsin, 200 mg/ml Dnase I) for 15 min at 37°C. A cell suspension was 
obtained by triturating the tissue with a pasteur pipette. The cell suspension 
was counted and seeded on poly-L-lysine coated plates. For neuronal culture, 
the medium was F12/DMEM with the supplement of 1% N2; for glial culture, 
the medium was F12/DMEM with 10% FBS. One week later, the cells were 
seeded in 48-well plates with density of 2 × 104 cells/well for transduction 
experiments. 
 
Plasmid DNA was diluted in 5% glucose to desired concentration. PEI (25 
kDa; Sigma-Aldrich, San Diego, CA, USA) was used as an aqueous stock 
solution containing 10 mM nitrogen. Ratio of PEI to DNA used for cell 
transfection was 10 equivalents of PEI nitrogen per DNA phosphate. The 
required amount of PEI was calculated by taking into account that 1 mg of 
DNA contains 3 nmol of phosphate, and that 1 ml of 10 mM PEI holds 10 nmol 
of amine nitrogen. Complexes were formed by adding the appropriate amount 
of PEI solution into the DNA solution, briefly mixing by vortexing and waiting 
for 30 min at room temperature. 10 ml of the PEI/DNA complexes containing 
0.5 mg plasmid DNA was added to each well with 100 ml of Opti-MEM 
(Invitrogen, Netherlands). PEI/DNA complexes were incubated with the cells 
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for 3 h at 37°C. The medium was then replaced with 200 ml of fresh complete 
medium and cells were further incubated at 37°C for appropriate time before 
subsequent experiments were carried out. 
 
For virus transduction, 100 ml of serum-free DMEM containing AAV-2 vectors 
or baculovirus vectors was added into each well at desired multiplicity of 
infection (MOI). One hour later, normal culture medium for the cells was 
restored. Cells were further cultured for various periods of time indicated 
before collected for luciferase activity measurement. After the incubation, cells 
were washed and permeabilized with 100 ml of reporter cell lysis buffer 
(Promega, WI, USA). Luciferase activities in cell extracts were measured 
using a luciferase assay kit (Promega, WI, USA) in a single-tube luminometer 
(Berthold Lumat LB 9507, Bad Wildbad, Germany) for 10 sec. The total 
protein concentration of each lysate was determined using the DC Protein 
Assay (Bio-Rad). The results were expressed in relative light units (RLU) per 
milligram of total protein. 
 
2.2.5  In vivo transduction with viral vectors and PEI/DNA complexes 
Adult male Wistar rats (weighing 250–320 g) were used throughout the study. 
Animals were kept in cages (two rats per cage) in a light–dark cycle (12 h/12 
h) at a constant temperature of 22°C and at 60% humidity, and fed with 
normal laboratory rat food. In the handling and care of all animals, the 
International Guiding Principles for Animal Research as stipulated by World 
Heath Organization (1985) and as adopted by the Laboratory Animal Center, 
National University of Singapore were followed. All animals were bred and 
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supplied by the Laboratory Animal Center, National University of Singapore, 
and kept in the animal unit before and after the experiments. 
 
Before each injection, the animals were anesthetized by intraperitoneal (i.p.) 
injection of sodium pentobarbital (60 mg/kg b.w.). The rats were positioned in 
a stereotaxic instrument with the tooth bar set at 0. A total volume of 10 ml of 
AAV-2 vectors, baculovirus vectors or PEI/DNA complexes were injected into 
the striatum at 2 injection points (AP ±1.0 mm, ML +2.5 mm, and DV -5.0 mm 
from bregma and dura), or the substantia nigra at 2 injection points (AP -5.4 
mm, ML +2.8 mm, and DV -7.2 mm; AP -5.4 mm, ML +1.8 mm, and DV -7.6 
mm from bregma and dura), using a 10 ml Hamilton syringe at a speed of 0.5 
ml/min. The needle was allowed to remain in place for another 5 min before 
being slowly retracted at the end of each injection. 
 
To prepare PEI/pDNA complexes for in vivo injection, plasmid DNA was 
diluted in 5% glucose. PEI (25 kDa; Sigma-Aldrich, San Diego, CA, USA) was 
used as an aqueous stock solution containing 10 mM nitrogen. Ratio of PEI to 
DNA was 14 equivalents of PEI nitrogen per DNA phosphate. Complexes 
were formed by adding the appropriate amount of PEI solution into the DNA 
solution, briefly mixed by vortexing and left to incubate for 30 min at room 
temperature. 
 
For luciferase activity assays, tissue samples from different brain regions 
were collected, and homogenized in PBS (100 ml PBS per 50mg tissue) by 
sonication for 10 sec on ice. Homogenized tissues were then centrifuged at 
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13 000 rpm for 10 min at 4°C. For each sample, 10 ml of the supernatant was 
used for the luciferase activity assay as stated above. The RLU from each 
tissue sample was calculated and the results were expressed as RLU per 
region. 
 
2.2.6  Immunohistochemistry analysis 
For immunohistochemistry analyses, anesthetized animals were perfused with 
100 ml PBS and followed by 400 ml of 4% paraformaldehyde in PBS. The 
brain was removed and equilibrated in a cryoprotectant solution of 20% 
sucrose in PBS and stored overnight in 4°C. Coronal sections with 30 μm 
containing the striatum or the substantia nigra were cut using a freezing 
sliding microtom. Free-floating sections were washed for 20 min in 0.1 M PBS 
at pH 7.4 containing 0.2% Triton X-100, then blocked with 5% normal goat 
serum in PBS for 1 hr. Sections from the striatum were incubated overnight 
with a polyclonal anti-luciferase (Promega, WI, USA; dilution 1:150) and a 
monoclonal antibody against neuron-specific nuclear protein (NeuN; 
Chemicon International, USA; dilution 1:150). Sections from the substantia 
nigra were incubated with a polyclonal anti-luciferase (Promega, WI, USA; 
dilution 1:150) and a monoclonal antibody against tyrosine hydroxylase (TH; 
Santa Cruz, CA, USA; dilution 1:150). Sections were then washed in 0.1 M 
PBS and further incubated with anti-rabbit IgG Tritc conjugate (Sigma-Aldrich, 
USA; dilution 1:500) and anti-mouse IgG FITC conjugate (Sigma-Aldrich, USA; 
dilution 1:500) for 1 hr. After the incubation, sections were washed three times 
in PBS, collected on gelatin-coated slides, mounted with DAKO fluorescent 
mounting medium, and covered with coverslips (Promega, WI, USA). Sections 
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were examined with an Olympus Fluoview 300 confocal laser scanning 
microscope. Each section was initially scanned with a 488 nm laser line, and 
an emission filter BP 510–530 for the detection of FITC fluorescein, then with 
a 543 nm laser line and an emission filter LP 560 for the detection of Tritc 
fluorescein. 
 
2.2.7 Southern blot analysis 
Baculovirus genomic DNA was extracted from 2×108 of BV-CMV E/PDGF-ITR 
using DNeasy tissue kit (Qiagen, Germany), and digested with Xho I, which 
released an 8.6-kb fragment containing the whole ITR-flanked expression 
cassette. Genomic DNA from NT-2 cells infected with equal amount of 
baculoviruses was extracted two days after the infection (MOI=100), and 
digested with Xho I.  Genomic DNA from NT-2 cells without virus infection was 
used as the control. After electrophoresis in 1% agarose gel, the digested 
DNA was transferred onto a nylon membrane, and hybridized with a DIG 
labeled probe that was PCR-amplified from the luciferase gene (1076-1318 nt 
from the ATG).  
 
2.2.8  Statistics 
Luciferase expressions from in vitro and in vivo transduction of AAV-2 vectors 
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2.3 Results 
2.3.1 In vitro and in vivo gene delivery with AAV-2 vectors carrying the 
hybrid CMV E/PDGF promoter 
2.3.1.1 Gene expression in cultured cells 
To generate AAV-2 vectors, the CMV promoter, the PDGF promoter and the 
hybrid CMV E/PDGF promoter constructed previously (Liu et al., 2004) were 
sub-cloned separately into a pAAV plasmid containing a firefly luciferase 
reporter gene. After co-transfection of the pAAV plasmids with the other two 
plasmids, pAAV-RC and pHelper, (1:1:1 molar ratio) into HEK293 cells, three 
AAV-2 recombinant vectors,  AAV-CMV, AAV-PDGF and AAV-CMV E/PDGF, 
with expression cassettes differing only in promoter fragments were produced.  
 
The study started with evaluation of the efficiency of transduction of the above 
three AAV-2 cassettes in cultured cells, including primary rat cortex neurons 
and glial cells, neuronally differentiated mouse C17.2 and human NT2N cells 
at MOI of 1,000. AAV-2 vectors carrying the CMV E/PDGF promoter mediated 
significantly higher levels of luciferase expression in primary cortical neurons 
than AAV-CMV and AAV-PDGF did, giving approximately 4 and 20-fold 
enhancement respectively at both 4 and 7 days after transduction (Fig. 2.3A & 
B). Improvement in gene expression by AAV-CMV E/PDGF was also 
noticeable in neuronally differentiated C17.2 and NT2-N cells (Fig. 2.3C). On 
the other hand, in primary glial cells, AAV-CMV mediated the strongest gene 
expression among the three AAV-2 cassettes tested and AAV-CMV E/PDGF 
did not improve gene expression significantly when compared to AAV-PDGF. 
The different performance of AAV-2 vectors with CMV E/PDGF in neurons 
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and glial cells indicates that the neuronal characteristic of the PDGF promoter 



















Fig. 2.3  Luciferase activity in primary cells and cell lines infected by AAV-2 
vectors with different promoters. Cortical neurons, glial cells and two neuronal 
cells (C17.2 and NT2N) were infected with AAV-CMV E/PDGF, AAV-CMV 
and AAV-PDGF respectively. Luciferase activity was measured 2 (C and D), 4 
(A) and 7 days (B) after the transduction, and expressed as RLU/mg protein 
(means ± S.D., n = 4). * P<0.05 compared with CMV or PDGF and + P<0.05 
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2.3.1.2  Gene expression in the striatum  
Given the encouraging observations in vitro, it was further investigated 
whether similar improvements could be achieved in the brain in vivo. Firstly, in 
vivo neuronal specificity of the expression mediated by AAV-2 vectors 
carrying the hybrid promoter was assessed. AAV-CMV E/PDGF (1 × 1010 
particles) was injected into the rat striatum and double immunostaining of 
brain sections was carried out 4 weeks later to visualize luciferase-positive 
cells and neurons. Fig. 2.4 shows that, in the region around the injection site, 
most of luciferase-expressing cells, around 90%, were positively stained by 
antibody against the neuron-specific nuclear protein (NeuN). While this 
specificity might be attributed to the neuronal tropism of AAV-2 vectors, it 
could be further enhanced by the retained neurotropism of the hybrid CMV 
E/PDGF promoter.  
 
Secondly, in vivo transgene expression mediated by the AAV-2 vectors with 
three different promoters were compared by quantitative luciferase activity 
assay. The comparison was done in a dose-dependent study, in which 4 
different doses of AAV-2 vectors ( 1×107 to 1×1010 particles per brain) were 
injected into the rat striatum and the brain tissues were collected four weeks 
later for the luciferase activity assay. AAV-CMV E/PDGF was again superior 
to the two controls, offering approximately 10-fold higher (P<0.05) luciferase 
activity than AAV-CMV and AAV-PDGF did at all the tested doses (Fig. 2.5). 
There was no significant difference between transduction efficiencies of AAV-
CMV and AAV-PDGF (Fig. 2.5).  
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Time course studies were then carried out to examine the duration of AAV-
mediated transduction in the brain. A low dose of AAV-2 vectors, 1 × 108 
particles per brain, was used in a 12-week study in order to exploit the 
opportunity of detecting possible decrease of gene expression within the 
experimental period. At most time points, luciferase expression from AAV-
CMV E/PDGF was significantly higher than that driven by AAV-CMV and 
AAV-PDGF, reaching its peak level at 4 weeks post-injection and remaining 
virtually unchanged for the following 8 weeks examined (Fig. 2.6A). Gene 
expression driven by AAV-PDGF slightly increased through the 12-week 
study, while gene expression from AAV-CMV decreased to 40% of its peak 
level at 2 weeks by the end of the study (Fig. 2.6A). To examine the 
transgene expression for a longer time course, two subgroups of rats (n = 2 
per each group) injected with AAV-CMV E/PDGF or AAV-CMV (1 × 1010 
particles per brain) were kept for 6 months after the injection. AAV-CMV 
E/PDGF provided luciferase activity of 1.1 + 0.5 x 107 RLU, equal to the level 
provided by the vector at 1 month (Fig. 2.5), whereas AAV-CMV produced 
luciferase activity of 2.2 + 1.6 x 105 RLU, which is about 20% of the gene 
expression driven by the same vector at 1 month (Fig. 2.5).  
 
The study also took the opportunity to compare the ability of the hybrid CMV 
E/PDGF promoter to drive sustained gene expression in the contexts of AAV-
2 vectors and plasmid vectors. One µg of plasmid DNA was complexed with 
cationic polymer PEI and injected into the rat stratum. Consistent with the 
previously published results (Liu et al., 2004), gene expression driven by the 
hybrid promoter placed in a plasmid vector and delivered through PEI/pDNA 
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complexes decreased gradually after the initial two weeks, although slower 
than that from CMV promoter (Fig. 2.6B). At the time point of 12 weeks post-
injection, the luciferase expression from the hybrid CMV E/PDGF promoter in 
the plasmid vector was only 5% of its level at week 1 (Fig. 2.6C). The 
corresponding value using AAV-2 vectors was 312% (Fig. 2.6C), indicating an 
improved stability of in vivo transgene expression when delivered with AAV-2 
























Fig. 2.4 Neuron specificity of luciferase expression mediated by AAV-CMV 
E/PDGF in the rat striatum. Four weeks after the injection of AAV-CMV 
E/PDGF, rat brains were collected. Coronal sections of the brains were used 
for double immunostaining against luciferase protein (Luc) to detect 
transfected cells and neuron-specific nuclear protein (NeuN) to reveal 















Fig. 2.5 Dose-dependent gene expression in the rat striatum using AAV-2 
vectors. AAV-CMV E/PDGF, AAV-CMV and AAV-PDGF were injected into the 
rat striatum at different doses indicated. Four weeks later, brain samples were 
collected and luciferase activity was measured. Four rats were used for each 
vector at each dose. The values presented as means ± S.D. (n=4). + P<0.01 




















Chapter 2. Hybrid Neuron-Specific Promoter 
 44 
 
Fig. 2.6 Time courses of luciferase expression in the rat striatum after 
injection of AAV-2 vectors or PEI/DNA complexes. 1 × 108 particles of AAV-
CMV E/PDGF, AAV-CMV and AAV-PDGF (A), or 1 μg of pGL3-CMV E/PDGF 
and pGL3-CMV (B) were injected into the rat striatum respectively. Brain 
samples were collected at various time points after the injection, and 
luciferase activities were measured. The values were presented as means ± 
S.D. (n=4). C: Comparison of time-dependent gene expressions from AAV-
CMV E/PDGF and pGL3-CMV E/PDGF. The luciferase activity at week 1 was 
set as 100. *P<0.01 as compared with CMV or PDGF (A) and *P<0.01 as 
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2.3.1.3  Gene expression in the substantia nigra 
A previous study reported that in dopaminergic neurons of the substantia 
nigra the PDGF promoter placed in AAV-2 vectors could drive transgene 
expression more efficiently than CMV promoter (Paterna et al., 2001). To take 
this finding further, the present study investigated whether AAV-CMV E/PDGF 
could enhance the expression in this brain area. Initially, the transgene 
expression in the substantia nigra achieved through possible retrograde 
axonal transport was examined after striatum injection of AAV-2 vectors. AAV-
CMV E/PDGF were injected into the striatum at a dose of 1 × 1010 particles 
per brain and luciferase expressionin in the substantia nigra, as well as at the 
injection area, were measured 4 weeks after the injection. While a high level 
of gene expression was obvious at the injection site, little expression could be 
detected in the substantia nigra (Fig. 2.7).  
 
In the subsequent experiment, local injections of 1 × 1010 particles of AAV-
CMV E/PDGF into the substantia nigra were performed. Rat brains were 
collected 4 weeks after the injection and luciferase activities in the substantia 
nigra as well as the striatum were assayed. The luciferase activity was found 
to be restricted within the substantia nigra, with a low activity being detectable 
in the striatum. Consistent with a previous report (Paterna et al., 2001), the 
PDGF promoter drove luciferase expression in the substantia nigra much 
more efficiently than CMV promoter did (Fig. 2.8). However, AAV-CMV 
E/PDGF provided the most efficient transgene expression, at levels 3- and 17-
fold higher than that provided by AAV-PDGF and AAV-CMV, respectively (Fig. 
2.7). Double immunostaining with antibodies against luciferase and tyrosine 
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hydroxylase (TH) revealed the high specificity of AAV-CMV E/PDGF in 
dopaminergic neurons, almost all luciferase positive cells also contained TH 


















Fig. 2.7 Luciferase expressions in the rat substantia nigra after injection of 
AAV-2 vectors into striatum or substantia nigra. 1 × 1010 particles of AAV-
CMV E/PDGF, AAV-CMV and AAV-PDGF were injected into either the rat 
striatum or substantia nigra. Four weeks later, the brain tissues from the 
substantia nigra region were collected, and used to measure the luciferase 
activity. The values were presented as means ± S.D. (n=4). * P<0.05 
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Fig. 2.8 Neuron specificity of luciferase expression mediated by AAV-CMV 
E/PDGF in the rat substantia nigra. Four weeks after the injection of AAV-
CMV E/PDGF into the rat substantia nigra, rat brains were collected. Coronal 
sections of the brains were used for double immunostaining against luciferase 
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2.3.2 In vitro and in vivo gene delivery with baculovirus vectors 
carrying the hybrid CMV E/PDGF promoter 
2.3.2.1 Gene expression in cultured cells 
Recombinant baculovirus vectors carrying luciferase reporter gene under the 
control of CMV promoter or hybrid CMV E/PDGF promoter, named BV-CMV 
and BV-CMV E/PDGF, were constructed and propagated in Sf9 cells 
according to the manufacturer’s instruction (Invitrogen, USA). Another 
baculovirus vector, named BV-CMV E/PDGF-ITR, was constructed with ITRs 
of AAV flanking a luciferase reporter gene expression cassette containing the 
CMV E/PDGF promoter, and prepared in parallel with the previous two 
baculovirus vectors. The titers (pfu) of the recombinant baculovirus vectors 
were determined by plaque assay on Sf9 cells. 
 
Transgene expression mediated by the generated baculovirus vectors was 
first examined in vitro in three neural cell lines, neuronally differentiated 
mouse C17.2, rat PC12 and human NT2N cells. Cells were infected with the 
three vectors at the same MOI of 25. Luciferase expression in the transduced 
cells was measured one, three and seven days after the infection (Fig. 2.9). At 
day 1, BV-CMV and BV-CMV E/PDGF-ITR produced 3 to 5-fold higher levels 
of gene expression than BV-CMV E/PDGF in three cell lines tested. BV-CMV-
mediated gene expression then decreased continuously over almost two 
orders of magnitude within 7 days and became about 3-fold lower than that 
mediated by BV-CMV E/PDGF by day 7 (P < 0.05). BV-CMV E/PDGF-ITR still 
provided a level of gene expression several folds higher than BV-CMV 
E/PDGF did at the two later time points and performed significantly better than 
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BV-CMV did, mediating 6, 8 and 13-fold higher levels of expression in PC12, 























Fig. 2.9 Dynamics of luciferase expression in cultured cells infected with 
recombinant baculoviruses. Neural C17.2, NT-2, and PC12 cells were 
infected with BV-CMV, BV-CMV E/PDGF or BV-CMV E/PDGF-ITR at the 
same MOI of 25. Luciferase expressions were measured one, three or seven 
days later. The results are presented in RLU per milligram of total protein 
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Several reports showed that the chromosomal integration or the high-
molecular-weight circular concatamers happened to transgenes flanked by 
ITRs in plasmid or viral vectors (Xiao et al., 1997; Duan et al., 1998). To 
explore the mechanism behind the improvement of transgene expression 
mediated by the ITRs in this study, southern blot analysis of NT-2 cells 
infected with BV-CMV E/PDGF-ITR with a MOI of 100 was carried out 2 days 
and 7 days after the infection. NT-2 cell without virus infection was used as 
the negative control, while genomic DNA extracted from BV-CMV E/PDGF-
ITR with equal amount to that used for NT-2 infection was used for 
comparison. Xho I was used to digest the DNA before agarose gel 
electrophoresis since it can release an 8.6 kb DNA fragment containing the 
whole ITR-flanked expression cassette from the genomic DNA of BV-CMV 
E/PDGF-ITR. A DIG-labeled probe PCR-amplified from the luciferase reporter 
gene was used to detect the DNA transferred on a nylon membrane. Fig. 2.10 
showed that, a DNA band slightly bigger than 8 kb can be detected in 
baculovirus genomic DNA, and also in DNA extracted from baculovirus-
infected NT-2 cells, with a decreased intensity from day 2 to day 7, which 
might be due to the degradation of virus DNA after entering into the cells. A 
DNA band with high molecular weight was also detected in all above-
mentioned DNA samples. This high-molecular weight band might be due to 
the incomplete digestion of genomic DNA of baculovirus. No extra DNA band 
could be detected in DNA extracted from NT-2 cells infected with baculovirus, 
as compared with DNA extracted from baculovirus. This result demonstrated 
that in NT-2 cells, the genome of BV-CMV E/PDGF-ITR remained episomal , 
and neither integrated into the chromosome nor formed the high-molecular-
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weight circular concatamers. Therefore, we can speculate that the improved 
transgene expression mediated by BV-CMV E/PDGF-ITR might be due to the 
promoter function of ITRs. 
 
Fig. 2.10 Southern blot analysis of NT-2 cells infected with BV-CMV E/PDGF-
ITR. Baculovirus genomic DNA was extracted from 2×108 of BV-CMV 
E/PDGF-ITR. Genomic DNA from NT-2 cells infected with equal amount of 
baculoviruses was extracted two days after the infection. DNAs were digested 
with Xho I. A DIG labeled probe amplified from the luciferase gene was used 
for the hybridization. Lane 1: DNA extracted from BV-CMV E/PDGF-ITR; lane 
2: DNA extracted from NT-2 cells; lane 3: DNA extracted from NT-2 cells 
infected with BV-CMV E/PDGF-ITR, 2 days post-infection. Lane 4: DNA 
extracted from NT-2 cells infected with BV-CMV E/PDGF-ITR, 7 days post-
infection. The positions of molecular size standards (kb) are indicated. 
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2.3.2.2  Gene expression in the brain 
In vivo gene transfer to the CNS was then carried out. 5 μl (5×107 pfu) of BV-
CMV, BV-CMV E/PDGF or BV-CMV E/PDGF-ITR were injected into the rat 
striatum, followed by analysis of luciferase expression at different time points 
up to 90 days (Fig. 2.11). BV-CMV mediated an initially high level of luciferase 
expression, which dropped sharply and was undetectable after 30 days. 
Luciferase expression achieved with BV-CMV E/PDGF also decreased over 
time but at a much slower rate, showing higher levels than those from BV-
CMV from day 8 onwards. Flanking the expression cassette with ITRs further 
improved transgene expression. This was particularly clear at day 90, the last 
time point in the study, when a relatively high level of gene expression from 
BV-CMV E/PDGF-ITR was still detectable, being 6-fold higher than that of BV-
CMV-E/PDGF (p < 0.01).  
 
 Previous study demonstrated that baculoviruses, after being internalized by 
nerve terminals at the injection site, could migrate by axonal transport to 
neuronal cell bodies located in a remote region (Li et al., 2004). This feature 
offers a unique opportunity to study specificity and activity of a promoter in 
neurons, as gene expression detected in a region remote from the injection 
site would be resulted purely neuronal. In the current study, analyses were 
carried out for gene expression mediated by the three baculovirus vectors in 
the striatum, the injection site, and in the cerebral cortex, a remote region 
where some of neurons have long axons projecting to the striatum. While 
luciferase activity from BV-CMV was detected mainly at the injection site (80% 
of total activity), the majority of luciferase activity, around 65% of total activity, 
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provided by the two viral vectors containing the neuron-specific CMV E/PDGF 
promoter was detected in the remote region (Fig. 2.12), suggesting that the 
hybrid promoter displayed a higher activity in cortical neurons than the CMV 
promoter. 
 
Neuronal specificity of the baculovirus vectors was further examined at the 
injection site by immunohistological staining. Two days after injection of 5 μl 
(1×108 pfu) BV-CMV E/PDGF, BV-CMV E/PDGF-ITR or BV-CMV into the rat 
striatum, brain tissue sections were collected for double immunostaining. Anti-
luciferase antibody was used to visualize transduced cells and anti-NeuN 
antibody was used to label neurons. Cell counting on the tissue sections 
around the injection site revealed that in BV-CMV E/PDGF-ITR injected 
samples, nearly 80% of transduced cells in the striatum were positively 
stained by NeuN antibodies (512 double-stained cells vs. 648 luciferase-
expressing cells). Similar results could be observed for BV-CMV E/PDGF 
injected samples. Among BV-CMV-transduced cells, only 5% were identified 
as neurons (38 double-stained cells vs. 820 luciferase-expressing cells) and 











































Fig. 2.11  Dynamics of luciferase expression in the rat brain after single 
injection of recombinant baculoviruses. For each rat, 5 μl (5 × 107 pfu) of BV-
CMV, BV-CMV E/PDGF or BV-CMV E/PDGF-ITR was injected into the 
striatum. Brain tissue samples were collected 2, 8, 30 and 90 days after 
injection for luciferase activity assay. Values are expressed as RLU per brain 
and presented as means ± S.D. (n=4). *, p<0.05 compared with BV-CMV 


















































Fig. 2.12 Activity of CMV E/PDGF promoter in cortical neurons after injection 
of baculovirus vectors into the striatum. Two days after viral vector injection 
described above (5 × 107 pfu per brain), rat brain tissues from the striatum 
(injection site) and the cerebral cortex tissues (remote region) were collected. 
Their luciferase activities were measured and expressed as RLU per region 




































































































Fig. 2.13 Immunohistological analysis of rat brains injected with recombinant 
baculoviruses. Five μl (1 × 108 pfu) of BV-CMV E/PDGF, BV-CMV E/PDGF-
ITR or BV-CMV was injected into the striatum of adult male Wistar rats. Two 
days after injection, brain samples were collected and double immunostaining 
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2.4  Discussion  
Combination of a viral enhancer element and a mammalian promoter has 
been tried in previous studies, with several studiesshowing improved activity 
of a mammalian promoter. In one of such studies using plasmid vectors, 
enhancers and promoters from muscle-specific genes were substituted for or 
combined with the CMV promoter and one of these chimeric vectors offered 
an expression level up to twice that of the parental plasmid (Barnhart et al., 
1998). Within AAV-2 vector, the CMV enhancer was used in combination with 
a 1.2 kb human skeletal actin promoter and increased transgene expression 
in the muscle significantly, providing a therapeutic range of coagulation factor 
IX at a 2- to 4-fold lower vector doses (Hagstrom et al., 2000). The most 
widely used hybrid promoter is probably the CAG promoter, which can direct 
improved expression in several tissues (Niwa et al., 1991; Xu et al., 2001a). 
The CMV enhancer also stimulated the EF1α promoter and the ubiquitin 
promoter (Kobayashi et al., 1997; Yew et al., 2001).  
 
The current study further confirmed the feasibility of using the CMV enhancer 
to positively stimulate a neuron-specific promoter in viral vectors for improved 
expression of transgene in the cultured neurons and in the brain. The 
mechanism underlying the enhancement is not clearly understood yet. It can 
only be speculated that transcriptional factors and auxiliary proteins attracted 
by the CMV enhancer may interact with those attracted by the PDGF 
promoter to generate a synergistic action that favors gene expression 
(Khachigian et al., 1995; Rafty and Khachigian, 1998). 
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 Neuron specificity 
The tissue/cell specificity of transgene expression is one of the crucial issues 
for gene therapy practice. AAV-2 has a natural tropism for neuronal cells, 
largely attributed to the specific recognizing and binding between its capsid 
protein and its receptor/co-receptors, including heparan sulfate proteoglycans 
(HSPGs), integrins (αvβ5) and fibroblast growth factor receptor 1 (FGF-R1). 
On the other hand, baculoviruses can infect a broad range of mammalian 
cells, and display a relatively higher tropism for glial cells than neurons in the 
CNS, when using a viral CMV promoter (Sarkis et al., 2000; Lehtolainen et al., 
2002). In this study, the hybrid CMV E/PDGF promoter, no matter in AAV-2 
vectors or baculovirus vectors, and drive strong neuron-specific transgene 
expression in the CNS, as shown by the immunostaining results (Fig. 2.4, Fig. 
2.8, Fig. 2.13).  
 
The PDGF B-chain is expressed in neurons throughout the CNS (Sasahara et 
al., 1991), suggesting its promoter would be active in all types of neurons. It 
should be possible to restrict the AAV- or baculovirus-mediated gene transfer 
to a particular sub-population of neurons after using a promoter that is active 
only in certain types of neurons. For example, a 1.2 kb dopamine β-
hydroxylase promoter or a synthetic promoter produced by multimerizing a 
noradrenergic-specific cis-regulatory element could be used to direct gene 
expression in noradrenergic neurons (Hwang et al., 2001). Such a gene 
delivery system specific to a subtype of neurons could be crucial for gene 
therapy in the brain, the most complicated organ of the body. Neuron types 
found in the brain are very diverse, many of which are critical to physiological 
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functions and highly sensitive to any kind of changes. This feature appeals 
strongly for the development of neuronal gene therapy that restricts the 
expression of a therapeutic gene to a specific type of neurons, thus 
minimizing side effects caused by gene expression in unintended types of 
neurons.  
 
Targeted delivery is another way to achieve cell type-specific gene 
expression. Retrograde axonal transportation has been used to target 
projection neurons in different regions by choosing an appropriate injection 
site either in the periphery or in more accessible sites in the CNS. The AAV-2 
transport from the injection site of the striatum to dopaminergic neurons in the 
subtantia nigra has been reported (Kaspar et al., 2002). However, most of 
other studies observed AAV-2 mediated-transgene expression limited mainly 
around the injection site (McCown et al., 1996; Lo et al., 1999; Mastakov et 
al., 2001). Consistent with the latter obervations, the present findings from a 
sensitive luciferase activity assay do not support the notion of effective axonal 
transport of AAV-2 from the striatum to the substantia nigra (Fig. 2.7).  
 
Levels of transgene expression  
In AAV-2 vectors, the PDGF promoter alone could drive higher level of 
transgene expression in certain CNS regions than CMV promoter did (Paterna 
et al., 2000). This effect appears to be subjected to intrinsic regulatory 
machineries in the subsets of neurons. The present study confirmed a higher 
activity of the PDGF promoter in the substantia nigra when compared with the 
CMV promoter. However, no significant difference in their activities in the 
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striatum was observed. The difference implies the existence of favorable 
transcriptional regulation for the PDGF promoter in dopaminergic neurons in 
the substantia nigra. 
 
Previous study using plasmid vectors demonstrated that the activity of the 
PDGF promoter could be augmented by the CMV enhancer in cultured 
neurons but not in the striatum, where its strength was still 10-fold lower than 
that from the CMV promoter within one week after the injection (Liu et al., 
2004). After being placed into an AAV-2 vector in the current study, the hybrid 
promoter displayed further improved strength in the striatum, resulting in an 
expression level similar to that driven by the CMV promoter during the first 
week. This observation demonstrated the effect of vector content on promoter 
activity.  
 
Other viral regulatory elements have also been applied in order to augment 
the activity of a mammalian promoter. For example, WPRE, an element 
required for the cytoplasmic accumulation of viral RNA (Donello et al., 1998), 
has been utilized to enhance the transgene expression by being incorporated 
into the 3’ region of transgenes (Paterna et al., 2000; Xu et al., 2001b). 
Incorporation of WPRE into the PDGF promoter-based AAV-2 vector resulted 
in 1.8-fold increase expression in dopaminergic neurons in the substanta 
nigra. The transduction remained stable for at least 41 weeks, probably the 
longest period of transgene expression demonstrated so far in the 
dopaminergic neurons by any viral vectors (Paterna et al., 2000). When used 
with the neuron-specific enolase (NSE) promoter, another cell type-specific 
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promoter that displays a high transcriptional activity in dopaminergic neurons, 
the WPRE sequence substantially improved the NSE-mediated transgene 
expression in the substanta nigra by 9-fold, with similar improvements 
observed as well in the striatum, hippocampus and cortex (Xu et al., 2001b).  
 
The hybrid approach adopted in the current study has enhanced the 
transcriptional activity of the PDGF promoter. However it might not be 
universally applicable to other promoters. In one of the previous studies that 
tested 19 different gene regulatory elements produced by combination of a 
muscle-specific promoter with the CMV enhancer, only one offered a 
significant increase in transgene expression compared to the control 
(Barnhart et al., 1998). The position of the CMV enhancer sequence relative 
to a mammalian promoter may vary in location, orientation and/or number, 
leading to hybrid promoters with varying degrees of activities. Rational design 
to enhance the transcriptional activity of a specific promoter by this hybrid 
approach requires analysis of the molecular mechanisms underlying their 
activity. Information about transcriptional regulatory elements, transcription 
factors and auxiliary proteins involved in the activity of the hybrid promoter 
may provide a clue for developing rational design strategies.        
 
Duration of transgene expression  
The current study examined the duration of transgene expression driven by 
the hybrid CMV E/PDGF promoter after placing it into either plasmid vectors 
that were then injected as polymer/pDNA complexes or AAV-2 vectors. It is 
still unclear whether the reduction of expression when using polymer/pDNA 
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complexes was due to plasmid elimination in the nucleus or promoter 
inactivation. The present study has nevertheless demonstrated clearly that a 
neuronal promoter alone, even if its activity has been enhanced, would not be 
sufficient to drive sustained gene expression in neurons. On the other hand, 
while AAV-mediated gene expression driven by either the PDGF promoter or 
the hybrid CMV E/PDGF promoter maintained till the end of 12 weeks in this 
study without any obvious reduction relative to their peak levels, CMV 
promoter-based AAV-2 vectors were unable to sustain the expression. A 
previous study reported 60% of reduction of gene expression from NSE 
promoter-based AAV-2 vectors within 3 months in the rat striatum (Xu et al., 
2001b). These findings have suggested that the AAV-2 vector structure alone 
may not be enough either to sustain gene expression in neurons. Such 
prolonged expression probably relies heavily upon the combination of a 
proper mammalian promoter, alone or together with certain supportive 
elements, and a vector like AAV-2.  
 
Whether an AAV-2 vector can integrate into a host chromosome or exist in the 
nucleus with an episomal state has been a topic of study since the beginning 
of using AAV-2 for gene delivery. A recent study in hepatocyes has 
demonstrated episomal genomes as the major form of AAV-2 vectors and the 
primary source of persistent gene expression from AAV-2 (Nakai et al., 2001). 
Vector genome concatemerization and/or the presence of the ITRs of AAV 
might be the possible mechanistic reasons for the episomal persistence in 
nuclei (Philip et al., 1994; Duan et al., 1998; Nakai et al., 2001). The AAV-2 
origins of DNA replication reside in the 145 bp ITRs that flank the AAV 
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genome. Plasmids flanked by ITRs, when transfected into several cell types, 
offered higher levels and wider distribution of gene expression that was more 
stable than plasmids without ITRs (Philip et al., 1994; Vieweg et al., 1995; 
Hsiao et al., 2001). It remains to be confirmed whether ITRs of AAV benefit 
neuronal gene expression in a similar way, whether episomal persistence of 
AAV-2 genome occurs in neurons, and, if so, whether it can mediate life-long 
expression of transgene.      
 
Baculovirus vectors with ITRs from AAV 
The transient gene expression mediated by baculoviruses limits their 
application for gene therapy of neurological disorders in the CNS. Previous 
studies have shown that peak levels of in vivo gene expression driven by the 
CMV promoter placed into baculovirus vectors last for just several days and 
drop quickly afterwards (Pieroni et al., 2001; Lehtolainen et al., 2002). In the 
case of the PDGF promoter, previous studies detected very low activity of the 
promoter, no matter whether it was placed into a plasmid, AAV or baculovirus 
vector. Due to the low activity of PDGF promoter, gene expression became 
undetectable after 2 to 3 days (Sarkis et al., 2000; Li et al., 2004; Liu et al., 
2004). Current study indicates clearly that PDGF promoter supported by CMV 
enhancer, within the context of baculovirus vectors is able to drive gene 
expression at a measurable level for 3 months.  
 
Further improvement of the gene expression was achieved when ITRs of AAV 
were incorporated into the baculovirus vectors (Fig. 2.9, Fig. 2.11). The 
findings that ITRs improved transgene expression driven by baculovirus 
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vectors are consistent with the observations made in Breakefield’s lab using 
herpes simplex virus-1 amplicon vectors containing ITRs (Johnston et al., 
1997; Costantini et al., 1999; Lam et al., 2002) and many other reports using 
plasmids containing ITRs (Philip et al., 1994; Vieweg et al., 1995; Fu et al., 
1998; Chou et al., 2001; Hsiao et al., 2001; Xin et al., 2003; Chikhlikar et al., 
2004). ITRs, however, were unable to change the dynamics of transgene 
expression. With or without ITRs, levels of gene expression from the two 
baculovirus vectors containing the hybrid CMV E/PDGF promoter declined at 
similar rates in both in vitro and in vivo experiments. Nevertheless, ITR-
augmented initial expression plus action of an enhanced cell type-specific 
promoter had made it possible to detect a relatively high level of transgene 
expression for at least 90 days in the brain. 
 
ITRs are crucial AAV elements, serving as primers for host cell-mediated DNA 
synthesis to convert the single-stranded viral DNA to a double-strand DNA 
template for transcription and replication (McCarty et al., 2004). A number of 
reports also suggested their roles in mediating a substrate DNA integration 
into the host chromosome (Xiao et al., 1997; Yang et al., 1997) and in defining 
integration boundaries of viral genome (Philpott et al., 2002). The presence of 
ITRs appears the only requirement for the formation of episomally stable 
concatemers of recombinant AAV genome that occur through intermolecular 
recombination between two independent linear and/or circular genomes 
(Duan et al., 1998; Yang et al., 1999). Interestingly, long-term transgene 
expression mediated by AAV vectors was found to be associated with the 
molecular conversion of single-stranded viral genomes to high-molecular-
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weight circular concatamers and prolonged episomal persistence of the 
concatemers, with a head-to-tail ITRs contained within the circular 
concatamers being responsible for mediating the increased persistence of 
transgene expression (Duan et al., 1998). Moreover, one study has shown 
that the ITRs of AAV could function directly as a promoter for expression of a 
reporter gene (Flotte et al., 1993). In view of all these possible functions of 
ITRs, it is not surprising that using them to flank a transgene cassette, in 
either a viral or a plasmid vector, helps to enhance and/or prolong gene 
expression in various cell types. The current study provides a new example 
showing the feasibility of improving gene expression driven by a baculovirus 
vector harboring a neuron-specific promoter in neurons.    
 
Size of the hybrid promoter 
The limited cloning capacity of the AAV-2 genome has led to concerns about 
the suitability of these vectors to deliver large therapeutic genes. With a 
natural genome of 4.7 kb, AAV-2 is unable to carry a foreign DNA larger than 
110% of its own genome, with 5 kb as the maximum size for both therapeutic 
gene and promoter components. To save enough room for a therapeutic 
gene, the promoter part of an AAV-2 vector should not be too large. The 
length of the hybrid promoter used in this study is about 1.8 kb, close to other 
promoters commonly used with AAV-2, like the neuron-specific enolase 
promoter (1.8 kb) and the hybrid CMV/chicken b-actin promoter (1.7 kb).  This 
relatively small size allows an AAV-2 vector carrying the hybrid promoter to 
take up a piece of 3 kb DNA, a length sufficient for the therapeutic genes 
commonly used for brain gene therapy, including nerve growth factor (NGF), 
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brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), etc. A 
recent study reported the use of the short human synapsin 1 gene promoter 
(hSYN, 480bp) in the context of AAV-2 vectors (Kugler et al., 2003). Including 
the CMV enhancer, as well as other regulatory elements like WPRE could be 
explored to further improve its strength. 
 
In conclusion, the in vitro and in vivo transgene expression driven by a 
previously constructed hybrid CMV E/PDGF promoter were examined in this 
study, with AAV-2 vector, baculovirus vector, or baculovirus vector with ITRs 
of AAV.  AAV-2 vector harboring this promoter could mediate an enhanced 
transgene expression in a neuron-specific manner, and more durable 
transgene expression than the plasmid vector. Moreover, the hybrid promoter 
could drive obviously higher transgene expression specifically in 
dopaminergic neurons in the substantia nigra, indicating important practical 
implications for gene therapy of PD. Baculovirus vector with this hybrid 
promoter could drive a high level and neuron-specific transgene expression, 
but only for a relatively short period of time. Furthermore, ITRs of AAV can 
improve the baculovirus-mediated transgene expression in vitro and in vivo by 
increasing the expression level for several folds.  In summary, the hybrid CMV 
E/PDGF promoter can be used for high level neuron-specific transgene 
expression in the brain by using viral vectors.  
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3.1 Introduction 
Astrocytes, the most abundant glial cells in the central nervous system (CNS), 
play crucial roles in supporting the survival and physiological functions of 
neurons. The importance of using these cells as gene transfer targets for the 
treatment of neuronal diseases and disorders has recently been 
demonstrated and discussed (Bohn, 2004). For example, increased 
expression of glial cell line-derived neurotrophic factor (GDNF) in astrocytes 
rescued motoneurons from programmed cell death and promoted their long 
term survival following axotomy (Zhao et al., 2004). Further, adenoviral 
vectors harboring GDNF driven by a glia-specific promoter delivered into the 
rat striatum increased the survival of dopaminergic neurons (Do Thi et al., 
2004). Neurotrophic factors that are secreted by neighboring astrocytes and 
act locally on nearby neuronal perikarya play important physiological roles, 
and act through retrograde transport mechanism on remote targets. In a 
pathological situation that affects axonal transport, physiological functions of 
neurotrophic factors produced by target tissues may be hampered or even 
totally blocked. Neurotrophic factors could help to sustain neuronal survival, 
slow down or stop degeneration processes of their axons, and probably also 
stimulate axonal regeneration. Moreover, gene transfer into astrocytes with 
neurotrophic factors might reduce gliosis, benefiting astrocyte-neuron 
interactions (Bohn, 2004). 
 
Among various gene delivery vectors that are capable of transducing glial 
cells is the baculovirus-based vector, a type of viral vector recently emerging 
as a new generation of gene therapy vehicle with great promise (Hofmann et 
Chapter 3. Hybrid Astrocyte-Specific Promoter 
 69 
al., 1995; Boyce and Bucher, 1996; Ghosh et al., 2002; Kost and Condreay, 
2002). Being non-mammalian, insect viruses, baculoviruses are unable to 
replicate in mammalian cells, thus significantly reducing the chance of 
provoking antiviral humoral and mammalian immunity in mammals. Other 
inherited advantages of baculoviruses as gene delivery vectors include the 
broad tropism for both proliferating and nonproliferating cells, the lack of 
obvious cytopathic effects, large cloning capacity and ease preparation of 
high titers of viruses. In systemic circulation, baculoviruses are inactivated 
easily after exposed to serum complements (Hofmann and Strauss, 1998). 
The CNS, protected by the blood-brain barrier (BBB), is virtually isolated from 
circulating immunological factors including complement components (Carson 
and Sutcliffe, 1999), and thus is a suitable organ for baculovirus-mediated 
gene delivery. Injection of baculovirus vectors to the brain resulted in 
satisfactory level of transgene expression (Sarkis et al., 2000; Li et al., 2004, 
2005). Attractively, baculovirus has a high tropism for astrocytes. One of the 
previous studies using Cy3-labelled baculoviruses demonstrated that about 
70% of the viruses injected into the striatum were taken in by astrocytes (Li et 
al., 2004).  
 
To restrict the transgene expression in astrocytes, the promoter of the glial 
fibrillary acidic protein (GFAP) is probably the most widely used (Su et al., 
2004). The GFAP promoter has been used for glial-specific transgene 
expression within several virus gene delivery systems (McKie et al., 1998; 
Ralph et al., 2000; Jakobsson et al., 2003, 2004). However, like many other 
mammalian promoters, the GFAP promoter displays a relatively weak 
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transcriptional activity when compared to many viral promoters, for example 
the promoter of cytomegalovirus (CMV) immediate-early gene. In order to 
improve its activity, a viral transcriptional regulatory element may be applied to 
the GFAP promoter. As demonstrated in chapter 2, hybrid CMV E/PDGF 
promoter functions preferentially in neurons and is effective in improving gene 
expression levels and prolonging gene expression in either a plasmid, AAV-2 
or baculovirus vector (Liu et al., 2004; Li et al., 2004, 2005). However, it was 
unclear whether such an approach would be applicable to an astrocyte-
specific promoter, like the GFAP promoter.   
 
Another reported approach that could improve the transgene expression 
driven by a mammalian promoter is flanking an expression cassette of interest 
with the inverted terminal repeats (ITRs) of AAV. Again, the feasibility of this 
approach in improving the activity of an astrocyte-specfiic promoter has not 
yet been assessed. The current study constructed recombinant baculovirus 
vectors using the GFAP promoter and set out to investigate whether the 
above two approaches, in particular when the CMV E and the ITRs of AAV 
are used together, could improve the transgene expression in an astrocyte-
specific manner, especially in vivo in the brain.  
 
3.2 Materials and methods 
3.2.1  Construction of plasmids containing the hybrid promoter 
To construct the hybrid CMV E/GFAP promoter, a CMV E (-568 to -187 
relative to the TATA box of the CMV promoter) amplified from pRC/CMV2 was 
inserted between the sites of Kpn I and Sac I of a pGL3-basic plasmid 
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(Promega, USA), and a GFAP promoter amplified from pDRIVE02-GFAP 
(InvivoGen, San Diego, CA, USA) was subsequently inserted at the 
downstream of the CMV E between the sites of Nhe I and Hind III. To 
construct the hybrid promoter with two copies of CMV E, namely 2 x CMV 
E/GFAP, an additional CMV E was inserted between the sites of Sac I and 
Nhe I. CMV promoter and GFAP promoter were inserted into the sites of Kpn I 
and Hind III to construct plasmids containing CMV promoter and GFAP 
promoter respectively.  Fig. 3.1 shows the expression cassettes of the 
recombinant plasmids used in this study. 
Fig. 3.1 Schematics of the expression cassettes of the recombinant pGL3 
plasmids used in this study. Abbreviations: CMV, the promoter of CMV 
immediate-early gene; CMV E, the enhancer of CMV immediate-early gene; 
GFAP, the promoter of glial fibrillary acidic protein; Luc, luciferase gene; pA, 
polyA tail.  
 
3.2.2  Construction of recombinant baculovirus vectors 
pFastBac1 plasmid (Gibco BRL, Life Technologies, Gaithersburg, MD, USA) 
was used for the construction of the hybrid promoter and was subsequently 
used for the construction of recombinant baculovirus vectors. To construct the 
hybrid CMV E/GFAP promoter, a CMV E was inserted into pFastBac1 
between the sites of Not I and Xba I, and a GFAP promoter amplified from 
pDRIVE02-GFAP (InvivoGen, San Diego, CA, USA) was subsequently 
inserted at the downstream of the CMV E between Xba I and Xho I. Two other 
GFAP Luc pA
pCMV
GFAP Luc pACMV EpCMV E/GFAP
p2 x CMV E/GFAP GFAP Luc pACMV E
CMV Luc pA
pGFAP
CMV E  
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constructions containing the CMV promoter or GFAP promoter were also 
constructed by inserting the promoters into pFastBac1 between the Not I and 
Xba I (for CMV) or Xba I and Xho I (for GFAP). Luciferase was used as the 
reporter gene for all the constructions and was inserted the downstream of the 
promoters, between the sites of Xho I and Hind III.  
 
For the construction of baculovirus vector with ITRs of AAV, an expression 
cassette containing a multiple cloning site (MCS), a reporter gene encoding 
luciferase, a SV40 polyA signal, and two ITR sequences at both ends was 
amplified from the pAAV plasmid, and inserted into pFB1 between Avr II and 
Sal I. The CMV E/GFAP promoter was then inserted between the sites of Kpn 
I and Hind III to drive the luciferase reporter gene.  Fig. 3.2 shows the 







Fig. 3.2 Schematics of the expression cassettes of the recombinant 
baculovirus vectors used in this study. Abbreviations: CMV, the promoter of 
CMV immediate-early gene; CMV E, the enhancer of CMV immediate-early 
gene; GFAP, the promoter of glial fibrillary acidic protein; Luc, luciferase gene; 
pA, polyA tail; ITR, inverted terminal repeats.  
 
 
Recombinant baculovirus vectors containing the promoters described above, 
named as BV-CMV E/GFAP, BV-CMV, BV-GFAP and BV-CMV E/GFAP-ITR 
respectively, were produced as described in chapter 2.   
GFAP Luc pA
BV-CMV
GFAP Luc pACMV EBV-CMV E/GFAP
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3.2.3 Plasmid transfection and virus infection 
For in vitro infection, primary glial cell cultures established from the cortices of 
embryonic Wistar rats at gestational day 20, and glioma cell lines including 
C6, U251 and BT325 were used. Cells were seeded in 48-well plates with 
densities of 20,000 cells/well. For plasmid transfection, plasmid DNA was 
prepared as described in chapter 2. PEI /DNA complexes were incubated with 
the cells for 3 hr at 37°C. The medium was then replaced with fresh complete 
medium and cells were further incubated at 37°C for appropriate time. For 
baculovirus infection, appropriate amounts of baculovirus vectors were added 
in 100 μl of serum-free DMEM, and incubated with the cells at 37°C for 1 hr. 
After the incubation, serum-free DMEM containing the viruses was replaced 
by fresh growth medium, and the cells were incubated at 37°C for appropriate 
times before the luciferase assay. For in vivo viral delivery, Rats were injected 
as described in chapter 2. 
 
3.2.4 Immunohistochemistry analysis 
Deeply anesthefied, rats were perfused with 0.1 M PBS (pH 7.4) solution 
followed by 4% paraformaldehyde in PBS. The brains were removed and 
postfixed in the same fixative for 2–4 hr before being transferred into 20% 
sucrose in 0.1 M PBS to incubate overnight at 4°C. Cryostat sections were cut 
at 30 μm thickness for free-floating immunostaining. A polyclonal anti-
luciferase (Promega, Madison, WI, USA; dilution 1:150) and a monoclonal 
anti-GFAP protein or a monoclonal anti-neuron-specific nuclear protein 
(NeuN; Chemicon International, USA; dilution 1:150) were used as primary 
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antibodies. Anti-rabbit IgG TRITC conjugate (Sigma–Aldrich, USA; dilution 
1:500) and anti-mouse IgG FITC conjugate (Sigma–Aldrich; dilution 1:500) 
were used as the secondary antibodies. Sections were examined as 
described in chapter 2. 
 
3.2.5 Luciferase assay 
For luciferase assay of in vitro transduction, transduced cells cultured in 48-
well plates were washed and permeabilized with 100 μl of reporter cell lysis 
buffer (Promega, WI, USA). The total protein concentration of each lysate was 
determined using the DC Protein Assay (Bio-Rad). For luciferase assay of in 
vivo transduction, tissue samples from different brain regions were collected, 
and homogenized in PBS (100 ml PBS per 50mg tissue) by sonication for 10 
sec in ice. Homogenized tissues were then centrifuged at 13000 rpm for 10 
min at 4°C. 10 ml of cell extract (in vitro) or supernatant of homogenized 
tissues (in vivo) were used for luciferase assay with a luciferase assay kit 
(Promega, WI, USA) in a single-tube luminometer (Berthold Lumat LB 9507, 
Bad Wildbad, Germany) for 10 sec. The results were expressed in relative 
light units (RLU) per milligram of total protein (in vitro) or per brain region (in 
vivo). 
 
3.2.6  Statistics 
Luciferase activity in in vitro and in vivo experiments was analyzed statistically 
with the Student’s t test.     
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3.3  Results 
3.3.1 Improved transgene expression in cultured cells using the hybrid 
CMV E/GFAP promoter   
Luciferase expression levels were compared following the transfection of 
primary rat glial cells and U251 human astrocytoma cells with four plasmid 
DNA (Fig. 3.3) complexed with PEI. As shown in Fig. 3.3, pCMV E/GFAP 
significantly improved the expression when compared with pGFAP, by about 
100-fold in two types of cells tested. The expression levels from the hybrid 
promoter were only slightly lower than those from the CMV promoter, which is 
considered to be one of the strongest transcriptional control elements. 
However, when two copies of the CMV E were placed upstream from the 
GFAP promoter, no improvement in gene expression was observed in primary 
glial cells and moderate improvement in U251 cells, but with an expression 
level still much lower than that provided by the vector with only one copy of 
the CMV E.   
 
Recombinant baculovirus vectors were then constructed by inserting the 
reporter gene encoding luciferase under the control of the CMV promoter, 
GFAP promoter, or the hybrid CMV E/GFAP promoter into the backbone of 
baculovirus and were named here BV-CMV, BV-GFAP, and BV-CMV 
E/GFAP, respectively. A fourth expression cassette was constructed by 
flanking the CMV E/GFAP promoter and the luciferase reporter gene with the 
ITRs of AAV and the generated recombinant baculovirus vector was named 
BV-CMV E/GFAP-ITR.  
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To evaluate the transduction efficiency of baculovirus in astrocytes, BV-CMV 
was first used to infect primary glial cells isolated from the rat cortices and 
double-immunostaining was carried out with an antibody against luciferase to 
visualize the transduced cells and an antibody against GFAP protein to 
visualize astrocytes. Immunohistochemical co-localization of two proteins was 
easily detected (Fig. 3.4A), with about 90% of GFAP-positive cells being 
transduced. Gene expression levels of the above recombinant baculoviruses 
with different expression cassettes were then compared in three glioma cells, 
rat C6, human U251 and BT325 cells, using a quantitative luciferase activity 
assay. Similar to what was observed by using plasmid vectors, the CMV E in 
the context of baculovirus could significantly increase the strength of the 
GFAP promoter by 10 to 100-fold, resulting in levels of gene expression close 
to those of the CMV promoter (Fig. 3.4B). With ITRs flanking, further 
improvement in gene expression was observed. When compared with BV-
CMV E/GFAP, BV-CMV E/GFAP-ITR increased the expressions at least 10-
fold in the three cell lines tested, reaching the levels significantly higher than 
those provided by BV-CMV (Fig. 3.4B). 
 
To test whether the CMV E and the ITRs of AAV could prolong transgene 
expression mediated by baculovirus vectors, an in vitro time course study was 
carried out using the above three cell lines and cell samples were collected 
one, three and seven days after viral infection for quantitative luciferase 
activity assays. As shown in Fig. 3.5, the levels of gene expression from BV-
CMV dropped much faster than those from BV-CMV E/GFAP and BV-CMV 
E/GFAP-ITR. BV-CMV resulted in higher levels of gene expression compared 
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to BV-CMV E/GFAP at the beginning in two cell lines, but became much lower 
than those from BV-CMV E/GFAP by day 7. Among three viral vectors tested, 
BV-CMV E/GFAP-ITR was the best, displaying the highest levels of gene 
expression at all the time points in the three cell lines.    
 
Fig. 3.3 Luciferase activity in primary glial cells and astrocytoma cells 
transfected with plasmids carrying four different promoters. Primary gilal cells 
from the rat cortex and human U251 astrocytoma cells were transfected with 
pCMV, pGFAP, pCMV E/GFAP and p2 x CMV E/GFAP respectively. 
Luciferase activity assays were preformed in quadruplicate one day after the 
transfection and the standard deviation (S.D.) is indicated with error bars. The 
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Fig. 3.4 Baculovirus-mediated transduction in cultured glial cells. A: Double 
immunostaining to confirm BV-CMV infection in rat primary glial cells. B: 
Activities of different regulatory elements in the context of baculovirus vectors. 
Cells were infected with different recombinant baculovirus vectors at the same 
multiplicity of infection (MOI = 25). Immunostaining in A and luciferase activity 
assays in B were performed one day after infection. For luciferase assays, 
results are expressed in RLU/mg protein and presented as mean + S.D. (n = 
4). *, p<0.05 compared with BV-GFAP; x, p<0.05 compared with BV-CMV 
E/GFAP; +, p<0.05 compared with BV-CMV. 
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Fig. 3.5 Time courses of luciferase expression in glioma cell lines infected 
with recombinant baculoviruses. Cells were infected with BV-CMV, BV-CMV 
E/GFAP or BV-CMV E/GFAP-ITR at the same MOI of 25. Luciferase activity 
assays were preformed in quadruplicate at one, three and seven days after 
the infection, and the S.D. is indicated with error bars. The results are 
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3.3.2 Astrocyte-specific transgene expression in the brain   
One of the critical issues in developing a hybrid promoter is whether the 
original cell type specificity of a mammalian promoter could be preserved after 
the promoter engineering. The present study examined this issue with two 
approaches, mainly for BV-CMV E/PDGF-ITR, the viral vector producing the 
highest expression levels. Firstly, immunohistochemical double staining was 
carried out. Two days after the injection of BV-CMV E/PDGF-ITR (1×109 viral 
particles per brain) into the rat striatum, brain tissue sections were collected 
for double immunostaining using anti-luciferase antibody to visualize 
transduced cells, anti-GFAP antibody or anti-NeuN antibody to reveal 
astrocytes or neurons (Fig. 3.6).  The luciferase-GFAP double staining 
demonstrated that almost all transduced cells in the striatum were GFAP-
positive. This was consistent with the finding from the luciferase-NeuN double 
staining in which almost no luciferase-positive cells were positively stained 
using anti-NeuN antibody.    
 
As mentioned in previous chapter, baculovirus can transducer neurons via 
retrograde traffic through the axon after being internalized by nerve terminals. 
This viral transport mechanism was also used to examine the cell type 
specificity of the newly developed vectors containing the hybrid CMV E/GFAP 
promoter by analyzing gene expression in the striatum, the injection site, and 
in the cerebral cortex, a remote region where some of neurons have long 
axons projecting to the striatum (Fig. 3.7). The luciferase expression from BV-
CMV was detected mainly in the injection site, with 85% of total expression in 
the striatum and 15% in the cerebral cortex, indicating certain activity of the 
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CMV promoter in neurons. When two baculovirus vectors, BV-CMV E/GFAP 
and BV-CMV E/GFAP-ITR, were tested, extremely low expression was 
detected in the cerebral cortex. As some leakage of viral vectors in the 
cerebral cortex during striatum injection was possible, this low level 
expression could be due to transduction of the leaked viral vectors in 
astrocytes of the cerebral cortex. These findings further confirm that the two 
baculovirus vectors containing the CMV E/GFAP promoter display extremely 
















































Fig. 3.6 Immunohistological analysis of rat brains injected with recombinant 
baculoviruses. Five ml (1 × 109 pfu) of BV-CMV E/GFAP-ITR was injected into 
the striatum. Two days after the injection, brain samples were collected and 
frozen 30 mm thick coronal sections of the brain, within ±0.5 mm from the 
injection site, were cut for free-floating immunostaining. The primary 
antibodies used were a polyclonal anti-luciferase from Promega (WI, USA; 
dilution 1:150) and a monoclonal antibody against GFAP or NeuN from 
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Fig. 3.7 Activity of CMV E/GFAP promoter in neurons as measured by 
luciferase expression in a brain region remote from an injection site. Two days 
after injection of viral vectors with different gene regulatory elements (1 × 109 
pfu per brain), rat brain tissues from the striatum (injection site) and the 
cerebral cortex tissues (remote region) were collected. Their luciferase 
activities were measured and expressed as RLU per region (means ± S.D., 
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3.3.3 Improved transgene expression in the brain  
To determine whether the enhanced and extended gene expression in 
cultured glial cells mediated by baculovirus vectors can be reproduced in vivo, 
viral transduction in the rat brain was examined after stereotaxical injection of 
the baculovirus vectors into the striatum. We used BV-CMV-E/GFAP-ITR as it 
display the highest activity in vitrom(Fig. 3.8A). Four doses of BV-CMV-
E/GFAP-ITR from 1 x 106 to 1x 109 viral particles per brain, were injected into 
the striatum, and brain tissue was collected 2 days later for the luciferase 
activity assay. A sharp increase in transgene expression, close to two orders 
of magnitude, was detected when the dose increased from 1 x 106 to 1 x 108 
viral particles per brain, followed by a smaller increase when using 1x 109 
particles per brain. This finding confirmed the baculoviruses with the CMV 
E/GFAP promoter were able to infect brain cells effectively. 
 
The transgene expression mediated by baculovirus vectors with four different 
types of expression cassettes was then compared in a 90-day time course 
study (Fig. 3.8B). A low dose of 5 × 107 particles per brain was tested in order 
to exploit the opportunity of detecting a possible decease of transgene 
expression within the experimental period. A low dose may also minimize the 
influence of upregulation of transcription factors by a concentrated viral 
preparation, which might activate the endogenous GFAP promoter. Viruses 
were injected into the striatum, followed by analysis of luciferase expression 
at different time points up to 90 days. BV-CMV mediated an initially high level 
of expression, which drop sharply, and was undetectable at 90 days. Same as 
tested in vitro, BV-GFAP performed poorly in the brain as well, mediating a 
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low level of initial expression, which became undetectable after 30 days. CMV 
enhancer increased luciferase expression levels by 10-fold in the BV-CMV 
E/GFAP-infected brain. The levels decreased over time as well but at a much 
slower rate in comparison to that from BV-CMV or BV-GFAP. ITR flanking of 
the expression cassette containing the hybrid CMV E/GFAP promoter further 
improve its performance. This virus resulted in 10 times higher luciferase 
expression levels compared to BV-CMV E/GFAP infection. The superior 
performance of BV-CMV E/GFAP-ITR over BV-CMV E/GFAP was maintained 
through the whole experimental period, although the luciferase expression 
























































Fig. 3.8 Baculovirus-mediated transduction in the brain. A: Dose-dependent 
effects of BV-CMV E/GFAP-ITR after striatum injection. Tissue samples were 
collected 2 days after injection for the luciferase activity assay. B: Time 
courses of luciferase expression in rat brains after single injection of 
recombinant baculoviruses into the striatum. BV-CMV, BV-GFAP, BV-CMV 
E/GFAP, or BV-CMV E/PDGF-ITR (5 × 107 pfu per brain) was injected into the 
rat striatum. Four rats per group were used at each time points. Brain tissues 
were collected 2, 8, 30, 90 days after the injection for luciferase activity 
assays. Values are expressed as RLU per brain and the standard deviation is 
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3.4 Discussion 
The current chapter described the development of baculovirus vectors for 
astrocytic transduction. Incorporation the CMV enhancer and ITRs of AAV into 
a baculovirus vector harboring the GFAP promoter increased the level and the 
durability of transgene expression compared to the control vector without the 
CMV enhancer or ITRs or that of the CMV promoter. The present study 
further demonstrates the preserved astrocyte specificity of the new 
baculovirus vectors. It provides a successful example of the use of viral 
regulatory elements to strengthen the activity of a mammalian promoter in the 
context of baculovirus vectors without changing its mammalian specificity. The 
new baculovirus vectors have advantages for gene targeting to the astrocytes 
that require a high-level gene expression over a relatively long period of time.  
  
Astrocyte specificity 
Cell type-specific promoters are of great interest to scientists working in the 
gene therapy field because of their potential in driving selective gene 
expression in target cells. This feature could be extremely valuable for gene 
delivery to the CNS, where various cell types have been implicated in many 
different types of physiological functions. In the last several years, specific 
mammalian location of the GFAP protein in the CNS has encouraged the wide 
use of the GFAP promoter for targeting transgene expression to astrocytes 
(Su et al., 2004). Up to now, high specificity of transgene expression in 
astrocytes driven by a GFAP promoter has been reported using adenovirus 
(Ralph et al., 2000), HSV (McKie et al., 1998), and lentivirus (Jackbsson et al., 
2003, 2004). The current study has baculovirus added to this list and further 
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pointed out that including tested viral regulatory elements into the GFAP 
expression cassette did not affect the specificity of the promoter.  
 
It has been reported that most cells transduced with AAV carrying a GFAP 
promoter appeared neuronal (Peel and Klein 2000; Xu et al., 2001b). As the 
ITRs of AAV could function directly as a promoter for expression of a reporter 
gene (Flotte et al., 1993), overriding the GFAP promoter by ITRs could 
possibly lead to the neuronal expression (Fitzsimons et al., 2002). This notion 
is, however, not supported by the observation from the current study where 
GFAP promoter has been used together with the ITRs. The current study 
addressed the cell specificity issue using both astrocytic and neuronal 
markers and identified astrocytes as the only type of cells expressing the 
transgene (Fig. 3.6). The possibility of neuronal transduction was further 
excluded by the retrograde axonal transport experiment (Fig. 3.7). Therefore, 
the reason for neuronal expression of GFAP-containing AAV remains an open 
question. Su et al. (2004) has recently reported that dependent on the 
transgene integration site and the attached sequence of a targeted gene in 
transgenic mice, a GFAP promoter could drive transgene expression at a 
significant level in neurons. It appears that mammalian specificity of a GFAP 
promoter needs to be assessed according to a specific application condition.       
 
Level and duration of transgene expression in astrocytes  
Compared with other mammalian promoters, the GFAP promoter has a 
relatively strong activity, and is capable of driving expression of a transgene 
representing up to approximately 0.2% of total brain protein (Smith et al., 
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1998). However, when compared with strong viral promoters, for example the 
CMV promoter, it is still weak, as demonstrated in the current study and also 
several other studies (Morelli et al., 1999; Biglari et al., 2004). This inherent 
weakness in driving gene expression might affect efficacy of certain gene 
therapy applications in the CNS that require a high level of expression of 
therapeutic genes. As mentioned above, appending a viral transcriptional 
regulatory element to a mammalian promoter has been attempted in previous 
studies, with several of them showing an improved activity of the mammalian 
promoter. In previous studies in attempt to strengthen the activity of the 
neuronal specific PDGF promoter, several hundred-fold improvement in vitro 
and around 10-fold in vivo could be typically observed (Liu et al., 2004; Li et 
al., 2004, 2005). The current study further confirmed the feasibility of using 
the CMV enhancer to positively stimulate an astrocyte-specific GFAP 
promoter in a baculovirus vector for an improved expression of transgene in 
the cultured glial cells and in the brain.  
 
Incorporation of ITRs of AAV in baculovirus vectors harboring the hybrid CMV 
E/GFAP promoter, further improved the expression level. Further 
investigations will be needed to clarify whether some of their functions might 
have contributed to the improved gene expression reported here.  
 
In conclusion, the current study provide a successful example of the use of 
viral regulatory elements to strengthen the transcriptional activity of a 
mammalian promoter in the context of baculovirus vectors without changing 
its specificity. New baculovirus vectors benefit from high-level of gene 
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expression over a relatively long period of time, and can be used for targeting 
genes to astrocytes. They could potentially be useful for gene therapy of 
neurons affected in neurological diseases through astrocytic transduction and 
a paracrine action of neurotrophic factors. It could also possibly be utilized for 
astrocyte-specific gene expression in glioma cells for brain cancer therapy. 
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4.1 Introduction 
The duration of transgene expression is one of the critical issues of gene 
therapy. Neurodegenerative disorders in the central nervous system (CNS) 
like Parkinson’s diseases (PD) usually require long-term expression of 
therapeutic genes in target neurons or glial cells. Adeno-associated virus type 
2 (AAV-2) vectors can mediate such long-term transgene expression, but are 
limited by the small cloning capacity for therapeutic genes and inconvenience 
of preparing large quantities of viral stock (Rabinowtz and Samulski, 1998; 
Ruitenberg et al., 2002). Moreover, the high neuronal tropism of AAV-2 vector 
makes it almost unsuitable for transduction of glial cells, an important target in 
the treatment of neurodegenerative conditions (Wu Du et al., 2002). On the 
other hand, baculovirus vectors have the merits of large cloning capacity and 
easy preparation, but can only mediate transient gene expression in neurons 
and glial cells (Kost and Condreay, 2002; Ghosh et al., 2002; Li et al., 2004). 
Even with the aid of Inverted terminal repeats (ITRs) of AAV, baculovirus-
mediated gene expression in the brain drops gradually after the initial peak, 
as shown in the previous two chapters. 
 
As has already been demonstrated, improved performance of gene delivery 
could be achieved by a hybrid viral vector constructed by incorporating the 
ITRs and the Rep gene, the two cis elements of AAV that are responsible for 
the long-term transgene expression, into the backbone of another viral vector 
like adenovirus or herpes simplex virus (HSV). The hybrid adenovirus-AAV 
vectors that can be manipulated conveniently and mediates long-term 
transgene expression in mammalian cells, were generated by inserting the 
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ITRs of AAV into the genome of adenovirus (Goncalves et al., 2002). Hybrid 
HSV-AAV amplicon vectors capable of directing high level and long-term 
transgene expression in glioma or primary neuronal cells were also produced 
(Johnston et al., 1997; Costantini et al., 1999). However, these hybrid viruses 
are not applicable for humans because of the immune responses and 
inflammation reactions caused by the components from adenovirus or HSV. 
 
Hybrid baculovirus-AAV vectors have been constructed by combining the key 
elements of AAV with the high transduction capacity of baculovirus (Palombo 
et al., 1998). The ITRs and the Rep gene, which mediate the site-specific 
integration of AAV genome into the AAVS1 locus of human chromosome 19, 
were incorporated into the genomic backbone of baculovirus. Infection of 
HEK293 (human embryonic kidney) cells with this hybrid vector resulted in 
sustained transgene expression and efficient chromosomal integration. While 
retaining the advantages inherited from the baculovirus, such as non-
pathogenicity, large cloning capacity, ease of preparation and ability to infect 
non-dividing cells (Shoji et al., 1997; Sarkis et al., 2000), this vector also 
mediate long-term transgene expression, essential for gene therapy of many 
CNS diseases. Since baculovirus is a relatively recent developed vector, its 
characteristics have not been clearly understood, and the application of this 
hybrid baculovirus-AAV vector for gene delivery has not been further 
investigated. 
 
In this chapter, hybrid baculovirus-AAV vectors carrying the CMV E/PDGF or 
CMV E/GFAP promoter were constructed for long-term, high level and 
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neuron- or astrocyte-specific transgene expression the CNS. The hybrid virus-
mediated gene expression was examined in vitro using neuronal and glial cell 
lines.  
 
4.2 Materials and methods 
4.2.1 Construction of hybrid baculovirus-AAV vectors 
Transfer vector pFastBac 1 (pFB1) was used to construct the hybrid 
baculovirus-AAV vector. pFB1 is a donor plasmid in which the foreign gene 
can be cloned and then transposed into baculovirus genome. In this study, a 
recombinant pFB1 plasmid, renamed as pHy that contains the ITRs of AAV, 
was firstly constructed as the backbone for further insertion of foreign genes 
and promoters. To construct pHy, an expression cassette containing a MCS 
(multiple cloning site), a reporter gene encoding luciferase, a SV40 polyA 
signal, and two ITRs at both ends was amplified from the pAAV plasmid, and 
inserted into pFB1 between the sites of Avr II and Sal I. Two promoters 
constructed in the previous chapters, CMV E/PDGF and CMV E/GFAP, were 
used to drive the luciferase reporter gene in the hybrid baculovirus-AAV 
vector, and were inserted into the plasmid pHy between Kpn I and Hind III 
respectively. A DNA fragment containing the full sequences of Rep gene was 
amplified from pSub201 (kindly provided by Professor RJ Samulski, Gene 
Therapy Center, the University of North Carolina, USA) that was first digested 
with Apa I to remove the encoding sequence of Cap gene and then self-
ligated again. The amplified Rep gene was inserted into the recombinant pHy 
plasmids containing the CMV E/PDGF promoter and CMV E/GFAP promoter 
at the Rsr II site respectively, outside the ITRs in the antisense orientation 
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with respect to the pPolh promoter. These two recombinant pHy plasmids in 
which the expression cassettes were flanked by ITRs and with the Rep gene 
were named as pHy-CMV E/PDGF and pHy-CMV E/GFAP respectively.  
 
These recombinant pHy plasmids were then used to produce hybrid 
baculovirus-AAV vectors, which were named as HyV-CMV E/PDGF and HyV-
CMV E/GFAP respectively, and produced, propagated and purified according 
to the manufacturer’s instructions. The titers (pfu, plaque forming unit) of the 
viruses were determined by plaque assay on sf9 insect cells, following the 
same procedures as described in the previous chapters. Four other 
baculovirus vectors, namely BV-CMV E/PDGF, BV-CMV E/PDGF-ITR, BV-
CMV E/GFAP and BV-CMV E/GFAP-ITR were constructed and produced as 

















Fig. 4.1 Expression cassettes of the recombinant baculovirus and hybrid 
baculovirus-AAV vectors used in this study. Abbreviations: CMV E: the 
enhancer of CMV immediate-early gene; PDGF: the promoter of platelet-
derived growth factor B chain; GFAP: the promoter of glial fibrillary acidic 
protein; Luc, luciferase gene; pA, polyA tail; ITR, inverted terminal repeats of 
AAV; Rep: the Rep gene of AAV. 
 
4.2.2 In vitro virus infection 
For in vitro viral infection, glioma cells U251 (human) and C6 (rat), and 
neuronal cells HCN-2 (human) and PC12 (Mouse) were used. Cells were 
seeded in 48-well plates with densities of 20,000 cells/well. After the 
attachment of the cells, appropriate amounts of hybrid baculovirus-AAV 
vectors or baculovirus vectors were added in 100 ml of serum-free DMEM, and 
incubated with the cells at 37°C for 1 hr. After the incubation, serum-free 
DMEM containing the viruses was replaced by fresh growth medium, and the 




CMV E/PDGF luc pA
CMV E/PDGF luc pAITR ITR
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4.2.3  Luciferase assay 
Transduced cells cultured in 48-well plates were washed with PBS and 
permeabilized with 100 μl of reporter cell lysis buffer (Promega, WI, USA). 
The total protein concentration of each lysate was determined by using the 
DC Protein Assay (Bio-Rad). 10 ml of cell extract was used for luciferase 
assay with a luciferase assay kit (Promega, WI, USA) in a single-tube 
luminometer (Berthold Lumat LB 9507, Bad Wildbad, Germany) for 10 sec. 
The results were expressed in relative light units (RLU) per milligram of total 
protein. 
 
4.2.4  Nested PCR 
Integration of ITR-flanked DNA in the AAVS1 site of chromosome 19 was 
determined by nested PCR with primer pairs that flank the AAV-chromosome 
junction. Primers Cr1 and Cr2 were located on the chromosome 19 around 
the AAVS1 site, while primers Luc1 and Luc2 were located within the 
luciferase gene that carried by the vectors. Cr1 and Luc1 were used for the 
first round of PCR amplification with 0.5 mg of genomic DNA that was 
extracted from cells infected by the hybrid viral vectors. The PCR amplification 
was carried out with initial incubation at 94°C for 4 min, followed by 30 cycles 
of amplification with 94°C for 1 min, 55°C for 1 min and 72°C for 2 min. One 
percent of the amplification product was diluted into a new PCR reaction using 
the Cr2 and Luc2 primers with the same PCR parameters. The product of 
second round PCR was analyzed on 1% agarose gel. The sequences of the 
oligo primers were as follow: 
Cr1: 5-GCGCGCATAAGCCAGTAGAGC 







4.3  Results 
4.3.1  In vitro transgene expression from hybrid viral vectors 
Transgene expressions from these hybrid baculovirus-AAV vectors were first 
examined in mammalian cell lines. Neuronal cells HCN-2 (human) and PC12 
(rat) were infected with HyV-CMV E/PDGF with MOI of 25. Two other 
constructions, BV-CMV E/PDGF, and BV-CMV E/PDGF-ITR that contains the 
ITRs only, were used for control experiments to infect the cells with the same 
MOI. The luciferase expressions from the infected cells were measured 3, 7 
and 14 days post-infection. The results showed that, in human-originated 
HCN-2 cells, a sustained transgene expression can be observed with the 
hybrid baculovirus-AAV which contains both the ITRs and the Rep gene, but 
not with that contain the ITRs only or original baculovirus vectors. At day 14, 
the luciferase activity in hybrid virus infected HCN-2 cells decreased to about 
50% of that at day 3, while the corresponding percentages were less than 
20% in HCN-2 cells infected with the baculovirus vectors or that with only the 
ITRs. In rat-originated PC12 cells, no significant differences could be 
observed between the hybrid virus and the control viruses. The transgene 
expression in PC12 cells transduced by all the three constructs decreased at 
similar rates (Fig. 4.2).  
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Gene expression in glial cells infected by hybrid baculovirus-AAV vectors with 
the CMV E/GFAP promoter was also examined. Glioma cells U251 (human) 
and C6 (rat) were infected with HyV-CMV E/GFAP, BV-CMV E/GFAP and BV-
CMV E/GFAP-ITR with MOI of 25 respectively, and the luciferase expression 
was measured 3, 7 and 14 days post-infection. Similarly, the results showed 
that a prolonged transgene expression could be achieved in human glioma 
cells, but not in rat cells with the hybrid baculovirus-AAV vector that contains 
both the ITRs and the Rep gene (Fig. 4.3).  In human-originated U251 cells 
infected with the hybrid baculovirus-AAV vectors, the luciferase activity at day 
14 decreased to 12.8% of that at day 3. The corresponding percentage 
decreased to about only 1% for U251 cells infected with original baculovirus 

















































Fig. 4.2 Transgene expressions in neuronal cells HCN-2 (top) and PC12 
(bottom) mediated by hybrid baculovirus-AAV vectors containing CMV 
E/PDGF promoter. Cells were infected with HyV-CMV E/PDGF, BV-CMV 
E/PDGF and BV-CMV E/PDGF-ITR at MOI of 25, and the luciferase 
expressions were measured 3, 7 and 14 days after the infection. The 
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Fig. 4.3  Transgene expressions in a human glioma cell line U251 (top) and a 
rat glioma cell line C6 (bottom) after the infection of hybrid baculovirus-AAV 
vectors containing CMV E/GFAP promoter. Cells were infected with HyV-CMV 
E/GFAP, BV-CMV E/GFAP and BV-CMV E/GFAP-ITR at MOI of 25, and the 
luciferase expressions were measured 3, 7 and 14 days after the infection. 
The luciferase expression at each time point was presented as RLU / mg 











Days post-infection  
106
107




Days post-infection  
Chapter 4. Hybrid Baculovirus-AAV Vector 
 102 
4.3.2 Site-specific integration mediated by hybrid baculoviru-AAV 
vectors in human-originated cells 
Site-specific integration mediated by the hybrid baculovirus-AAV vector was 
then examined on human-originated cell lines. Neuronal cells HCN-2 were 
infected with HyV-CMV E/PDGF or BV-CMV E/PDGF-ITR, while glioma cells 
U251 were infected with HyV-CMV E/GFAP or BV-CMV E/GFAP-ITR 
respectively with MOI of 25. Four days after the infection, genomic DNAs of 
the infected cells were extracted, and were used for the amplification of ITR-
AAVS1 junction by nested PCR, in which two sets of primers specific for the 
luciferase gene and the AAVS1 of chromosome 19 were used. As shown in 
Fig. 4.4, specific DNA bands were amplified from HCN-2 cells or U251 cells 
infected with the hybrid baculovirus-AAV vectors, but not from cells infected 
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Fig. 4.4  Site-specific integration mediated by hybrid baculovirus-AAV vectors. 
HCN-2 cells were infected with HyV-CMV E/PDGF and BV-CMV E/PDGF-
ITR, while U251 cells were infected with HyV-CMV E/GFAP and BV-CMV 
E/GFAP-ITR at MOI of 25 respectively. Four days after the infection, genomic 
DNAs were extracted and nested PCR were carried out to amplify the ITR-
AAVS1 junction. +: BV-CMV E/PDGF-ITR or BV-CMV E/GFAP-ITR; ++: HyV-
CMV E/PDGF or HyV-CMV E/GFAP.  The amplified bands with about 800 bp 
are indicated with arrows. The molecular size standards (kb) are indicated. 
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4.4 Discussion  
The application of baculoviruses as delivery vectors for gene therapy of 
neurological diseases was hampered by their transient gene expression 
profile, while the obstacles for applying AAV vectors for gene delivery to the 
CNS include their small capacity for foreign genes and inconvenience of 
preparation. The hybrid baculovirus-AAV vectors may be able to overcome 
the limitations from both baculovirus and AAV vectors, making themselves 
promising vehicles for long-term expression of the therapeutic genes. In this 
part of the study, hybrid baculovirus-AAV vectors carrying the neuron-specific 
CMV E/PDGF promoter or astrocyte-specific CMV E/GFAP promoter were 
produced, and transgene expression mediated by them was examined. 
Consistent with the previous report (Palombo et al., 1998), a sustained 
transgene expression could be observed with the hybrid baculovirus-AAV 
vectors in cell lines of humans, and the site-specific integration of the 
transgene into the AAVS1 locus of chromosome 19 was also confirmed. 
 
ITRs and Rep gene of AAV 
Wild-type AAV can integrate its genome into the AAVS1 locus of human 
chromosome 19 via combined actions of the ITRs and the Rep gene. 
Recombinant AAV vectors, in which Rep gene has been replaced by the 
exogenous genes, can still mediate long-term transgene expression, not only 
in human cells, but also in non-human cells. It has been reported that long-
term transgene expression mediated by recombinant AAV vector is associated 
with the molecular conversion of single-stranded viral genomes to high-
molecular-weight circular concatamers in head-to-tail orientation which remain 
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episomally for a long time (Duan et al., 1998). Although ITRs alone can 
mediate long-term transgene expression in recombinant AAV vector, it seems 
that they are insufficient for the purpose in the backbone of baculovirus vector, 
as shown by the present results and a previous report. In both cases long-
term transgene expression could only be achieved when the ITRs used 
together with the Rep gene (Palombo et al., 1998). The reasons behind the 
phenomena might be that, in the recombinant AAV vector, the ITRs are 
located at the ends of the genome, and therefore a high-molecular-weight 
circular concatamers can be easily formed. In hybrid baculovirus-AAV vector, 
the ITRs are in the middle of the baculovirus genome, which prevents the 
ITRs from forming a circular concatamer.  
 
Duration of the transgene expression 
In human-originated cell lines like HCN-2 and U251, hybrid baculovirus-AAV 
vectors can mediate more stable transgene expression as compared to 
baculovirus vectors or baculovirus vectors with ITRs only. The hybrid 
baculovirus-AAV vector can also mediate site-specific integration of its 
transgene into human chromosome 19, but the integration might not 
happened to all the transgene DNA taken up by the infected cells. Only part of 
the hybrid virus transgene will integrate into the chromosome. That might be 
the reason that the hybrid virus-mediated transgene expression decreased as 
well in cultured cells, although at much slower rate. It might be anticipated that 
if the hybrid virus-infected cells could eventually give rise to a stable clone.  
The speed of cell division might be another factor affecting the dynamics of 
transgene expression. During the cell division, the transgene DNA which is 
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not integrated into the chromosome will be diluted. The faster the cell divides, 
the faster the decline of the transgene expression will be. As shown in this 
study, the transgene expression in the U251 cells decreased much faster than 
that in the HCN-2 cells, a normal neuronal cell line with a very slow growth 
rate, and a doubling time of about 10 days.  
 
Cell type specificity 
The hybrid CMV E/PDGF promoter and CMV E/GFAP promoter constructed 
in previous two chapters have proven to drive neuron- or astrocyte-specific 
transgene expression in the CNS with the baculovirus vectors. By using those 
cell type-specific promoters in the hybrid baculovirus-AAV vectors, long-term 
neuron- or astrocyte-specific transgene expression might hopefully be 
achieved. The cell type specificity of the long-term transgene expression is  
critical since the transduction of unintended cells in the CNS might cause 
severe side effects. Although the in vivo transduction by this hybrid 
baculovirus-AAV vectors with the hybrid promoters has not been examined in 
this study, it can be anticipated that the cell type specificity of the hybrid CMV 
E/PDGF and CMV E/GFAP promoters can be reserved in the hybrid 
baculovirus-AAV vectors. 
 
Cytotoxicity of Rep proteins 
The Rep protein has been reported to be cytotoxic to mammalian cells 
(Schmidt et al., 2000). In this study, apoptotic cell death in cells infected with 
high dose of hybrid viral vector was also observed, e.g. at MOI of 500 (data 
not shown). Usage of hybrid promoters with high transcriptional activities in 
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the baculovirus-AAV vector can minimize the cytotoxicity of Rep expression. 
With strong promoters such as the hybrid CMV E/PDGF or CMV E/GFAP 
promoter, the transgene expression was quite high even at a very low MOI 
such as 25. No obvious cell death was observed as such a low MOI, although 
the cytotoxicity of Rep expression needed to be further comfirmed.  
 
Applications of the hybrid baculovirus-AAV vectors 
The hybrid viral vector developed in this chapter can be applied for gene 
therapy of neurodegenerative diseases in the CNS such as Parkinson’s 
disease and Alzheimer’s disease, which usually require long-term and high 
level expressions of therapeutic genes. Targeted delivery of therapeutic 
genes like GDNF to neurons in the substantia nigra can prevent the loss of 
dopaminergic neurons, therefore preventing the development of Parkinson’s 
disease. Astrocyte-specific expression of BDNF or tyrosine hydroxylase has 
also been used for therapy of Parkinson’s disease (During et al., 1994; 
Raymon et al., 1997; Costantini et al., 2000). By using the hybrid baculovirus-
AAV vectors with strong and cell type-specific promoters, long-term, high level 
and cell type-specific expression of therapeutic genes can be feasible for the 
treatment of Parkinson’s disease. 
 
Genetically modified stem cells have recently been proposed for gene therapy 
of neurological diseases, especially gliomas in the CNS, because of their 
ability to trace the tumor or damaged cells (Aboody et al., 2000). However, 
stable transfection of the stem cells with the therapeutic genes by using 
antibiotic resistance screening is very time consuming. The hybrid 
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baculovirus-AAV vectors constructed in this study could be used to genetically 
modify the stem cells by site-specific integration of the therapeutic gene into 
their chromosome.   
 
In conclusion, the present study constructed hybrid baculovirus-AAV vectors 
by incorporating the ITRs and the Rep gene of AAV into the genomic 
backbone of baculoviruses. Using the hybrid promoters described might allow 
high level, cell type-specific and long-term transgene expression can be 
hopefully achieved with this hybrid baculovirus-AAV vector. Such vectors 
could be used for gene therapy of neurological diseases that require long-
term, high level and cell type-specific expression.  
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The ultimate purpose of this study was to develop suitable delivery systems 
with novel promoters and viral vectors for gene therapy of disorders of the 
central nervous system (CNS), particularly Parkinson’s disease and malignant 
glioma tumors.  Promoters and viral vectors are the focuses of this study to 
achieve high level, cell type specific and long term transgene expression in 
the CNS. 
 
By adding the enhancer of cytomegalovirus immediate-early gene (CMV E) 
upstream of mammalian promoters, hybrid CMV E/PDGF and CMV E/GFAP 
promoters were constructed. Improved transcriptional activities and retained 
cell type specificity were observed in vitro and in vivo by using AAV-2 and 
baculovirus vectors. Furthermore, ITRs of AAV were demonstrated to improve 
the baculovirus-mediated transgene expression.  
 
To overcome the inherited disadvantages of AAV-2 vectors and baculovirus 
vectors, a hybrid baculovirus-AAV vector was constructed by placing the 
essential elements of AAV, ITRs and Rep gene, which are responsible for 
site-specific integration of AAV, into the backbone of baculovirus vector. 
These hybrid vectors carrying the CMV E/PDGF promoter or CMV E/GFAP 
promoter could mediate more sustained transgene expression in human-
originated cell lines. Site-specific integration of the transgene delivered by the 
vectors into the AAVS1 locus on chromosome 19 was observed.  
 
The present study applied the strategy of placing the CMV enhancer 
upstream of PDGF or GFAP promoter to create hybrid promoters, and 
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achieved improved expression from these hybrid promoters in the CNS. 
However, the applicability of this strategy depends largely on the interaction 
between the transcription factors attracted by the CMV enhancer and those by 
the cell type-specific promoter, which might not always have a positive effect 
on the transgene expression as achieved in this study.  
 
In vivo gene delivery with the hybrid baculovirus-AAV vectors has yet to be 
performed, but hopefully a high level, cell type-specific and long-term 
transgene expression could be achieved. Although only luciferase reporter 
gene was tested in this study, therapeutic genes such as those encoding 
neuronal trophic factors can easily replace the reporter gene for future 
research. In addition, cell toxicity and immunogenicity of this gene delivery 
system should be examined before it can be applied on humans. 
Nevertheless, the present results have provided a solid basis for further 
preclinical research that may lead to the clinical application of the gene 
delivery systems constructed in this study.  
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